Document:

Amendment dated November 15, 2012 to Employment Agreement Ronald J. Masciantonio

 Exhibit 10.1 

 
 

 
 November 15, 2012 
 VIA HAND DELIVERY 
 Ronald J. Masciantonio 

c/o Destination Maternity Corporation 
 456 North
Fifth Street 
 Philadelphia, PA 19123 
  

	Re:	Executive Employment Agreement dated as of July 16, 2009 (as amended April 27, 2010, August 10, 2011, and November 22, 2011, the
“Agreement”) by and between Destination Maternity Corporation (the “Company”) and Ronald J. Masciantonio (“Executive” or “you”).

 Dear Ron: 
 Reference
is hereby made to the above referenced Agreement. Effective as of the date of this letter, each of the Company and you agree that Section 2 of the Agreement is hereby amended to provide that your title is hereby changed to “Executive Vice
President, Chief Administrative Officer & General Counsel.” 
 All terms of the Agreement, except as expressly modified by this
letter agreement, are hereby acknowledged and ratified. If you are in agreement with the terms of this letter agreement, please execute and return a fully executed copy of this letter agreement to me. 

 

	
	 Regards,
  

	 /s/ Edward M. Krell
 Edward M. Krell
 Chief Executive Officer

  

	
	 AGREED AND ACKNOWLEDGED:

 

	 /s/ Ronald J. Masciantonio
 Ronald J. Masciantonio
 Date: November 15, 2012EX-10.1

 Exhibit 10.1 
 CONTINGENT VALUE RIGHTS AGREEMENT 
 by and between 

WRIGHT MEDICAL GROUP, INC. 
 and 
 AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC

 Dated as of [ — ] 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	  	 	1	  
			
	 SECTION 1.1
	  	 Definitions
	  	 	1	  
			
	 SECTION 1.2
	  	 Compliance and Opinions
	  	 	13	  
			
	 SECTION 1.3
	  	 Form of Documents Delivered to Trustee
	  	 	13	  
			
	 SECTION 1.4
	  	 Acts of Holders
	  	 	14	  
			
	 SECTION 1.5
	  	 Notices, etc., to Trustee and Company
	  	 	15	  
			
	 SECTION 1.6
	  	 Notice to Holders; Waiver
	  	 	15	  
			
	 SECTION 1.7
	  	 Conflict with Trust Indenture Act
	  	 	16	  
			
	 SECTION 1.8
	  	 Effect of Headings and Table of Contents
	  	 	16	  
			
	 SECTION 1.9
	  	 Benefits of Agreement
	  	 	16	  
			
	 SECTION 1.10
	  	 Governing Law
	  	 	16	  
			
	 SECTION 1.11
	  	 Legal Holidays
	  	 	17	  
			
	 SECTION 1.12
	  	 Separability Clause
	  	 	17	  
			
	 SECTION 1.13
	  	 No Recourse Against Others
	  	 	17	  
			
	 SECTION 1.14
	  	 Counterparts
	  	 	17	  
			
	 SECTION 1.15
	  	 Acceptance of Trust
	  	 	18	  
			
	 SECTION 1.16
	  	 Termination
	  	 	18	  
		
	 ARTICLE 2 SECURITY FORMS
	  	 	18	  
			
	 SECTION 2.1
	  	 Forms Generally
	  	 	18	  
		
	 ARTICLE 3 THE SECURITIES
	  	 	19	  
			
	 SECTION 3.1
	  	 Title and Payment Terms
	  	 	19	  
			
	 SECTION 3.2
	  	 Registrable Form
	  	 	20	  
			
	 SECTION 3.3
	  	 Execution, Authentication, Delivery and Dating
	  	 	21	  
			
	 SECTION 3.4
	  	 Registration, Registration of Transfer and Exchange
	  	 	21	  
			
	 SECTION 3.5
	  	 Mutilated, Destroyed, Lost and Stolen Securities
	  	 	24	  
			
	 SECTION 3.6
	  	 Payments with Respect to CVRs
	  	 	25	  
			
	 SECTION 3.7
	  	 Persons Deemed Owners
	  	 	25	  
			
	 SECTION 3.8
	  	 Cancellation
	  	 	25	  
			
	 SECTION 3.9
	  	 CUSIP Numbers
	  	 	25	  
		
	 ARTICLE 4 THE TRUSTEE
	  	 	26	  
			
	 SECTION 4.1
	  	 Certain Duties and Responsibilities
	  	 	26	  

							
			
	 SECTION 4.2
	  	Certain Rights of Trustee	  	 	27	  
			
	 SECTION 4.3
	  	Not Responsible for Recitals or Issuance of Securities	  	 	28	  
			
	 SECTION 4.4
	  	May Hold Securities	  	 	28	  
			
	 SECTION 4.5
	  	Money Held in Trust	  	 	29	  
			
	 SECTION 4.6
	  	Compensation and Reimbursement	  	 	29	  
			
	 SECTION 4.7
	  	Disqualification; Conflicting Interests	  	 	29	  
			
	 SECTION 4.8
	  	Corporate Trustee Required; Eligibility	  	 	30	  
			
	 SECTION 4.9
	  	Resignation and Removal; Appointment of Successor	  	 	30	  
			
	 SECTION 4.10
	  	Acceptance of Appointment of Successor	  	 	32	  
			
	 SECTION 4.11
	  	Merger, Conversion, Consolidation or Succession to Business	  	 	32	  
			
	 SECTION 4.12
	  	Preferential Collection of Claims Against Company	  	 	32	  
		
	 ARTICLE 5 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY
	  	 	33	  
			
	 SECTION 5.1
	  	Company to Furnish Trustee with Names and Addresses of Holders	  	 	33	  
			
	 SECTION 5.2
	  	Preservation of Information; Communications to Holders	  	 	33	  
			
	 SECTION 5.3
	  	Reports by Trustee	  	 	33	  
			
	 SECTION 5.4
	  	Reports by Company	  	 	34	  
			
	 SECTION 5.5
	  	Compliance Certificate	  	 	34	  
		
	 ARTICLE 6 AMENDMENTS
	  	 	35	  
			
	 SECTION 6.1
	  	Amendments without Consent of Holders	  	 	35	  
			
	 SECTION 6.2
	  	Amendments with Consent of Holders	  	 	35	  
			
	 SECTION 6.3
	  	Execution of Amendments	  	 	36	  
			
	 SECTION 6.4
	  	Effect of Amendments; Notice to Holders	  	 	36	  
			
	 SECTION 6.5
	  	Conformity with Trust Indenture Act	  	 	36	  
			
	 SECTION 6.6
	  	Reference in Securities to Amendments	  	 	37	  
		
	 ARTICLE 7 COVENANTS
	  	 	37	  
			
	 SECTION 7.1
	  	Payment of Amounts, if any, to Holders	  	 	37	  
			
	 SECTION 7.2
	  	Maintenance of Office or Agency	  	 	37	  
			
	 SECTION 7.3
	  	Money for Security Payments to Be Held in Trust	  	 	38	  
			
	 SECTION 7.4
	  	Certain Purchases and Sales	  	 	39	  
			
	 SECTION 7.5
	  	Books and Records	  	 	39	  
			
	 SECTION 7.6
	  	Audits	  	 	39	  
			
	 SECTION 7.7
	  	Listing of CVRs	  	 	40	  
			
	 SECTION 7.8
	  	Product Transfer	  	 	40	  

							
			
	 SECTION 7.9
	  	Milestones	  	 	41	  
			
	 SECTION 7.10
	  	Notice of Breach	  	 	42	  
			
	 SECTION 7.11
	  	Non-Use of Name	  	 	42	  
		
	 ARTICLE 8 REMEDIES OF THE TRUSTEE AND HOLDERS IN THE EVENT OF BREACH
	  	 	42	  
			
	 SECTION 8.1
	  	Breach Defined; Waiver of Breach	  	 	42	  
			
	 SECTION 8.2
	  	Collection by the Trustee; the Trustee May Prove Payment Obligations	  	 	43	  
			
	 SECTION 8.3
	  	Application of Proceeds	  	 	45	  
			
	 SECTION 8.4
	  	Suits for Enforcement	  	 	46	  
			
	 SECTION 8.5
	  	Restoration of Rights on Abandonment of Proceedings	  	 	46	  
			
	 SECTION 8.6
	  	Limitations on Suits by Holders	  	 	46	  
			
	 SECTION 8.7
	  	Unconditional Right of Holders to Institute Certain Suits	  	 	47	  
			
	 SECTION 8.8
	  	Powers and Remedies Cumulative; Delay or Omission Not Waiver of Breach	  	 	47	  
			
	 SECTION 8.9
	  	Control by Holders	  	 	47	  
			
	 SECTION 8.10
	  	Waiver of Past Breaches	  	 	48	  
			
	 SECTION 8.11
	  	The Trustee to Give Notice of Breach, But May Withhold in Certain Circumstances	  	 	48	  
			
	 SECTION 8.12
	  	Right of Court to Require Filing of Undertaking to Pay Costs	  	 	48	  
		
	 ARTICLE 9 CONSOLIDATION, MERGER, SALE OR CONVEYANCE
	  	 	49	  
			
	 SECTION 9.1
	  	Successor Person Substituted	  	 	49	  
			
	 SECTION 9.2
	  	Opinion of Counsel to the Trustee	  	 	49	  
			
	 SECTION 9.3
	  	Successors	  	 	50	  
		
	 ARTICLE 10 SUBORDINATION
	  	 	50	  
			
	 SECTION 10.1
	  	Agreement to Subordinate	  	 	50	  
			
	 SECTION 10.2
	  	Liquidation; Dissolution; Bankruptcy	  	 	50	  
			
	 SECTION 10.3
	  	When Distribution Must be Paid Over	  	 	51	  
			
	 SECTION 10.4
	  	Notice by Company	  	 	51	  
			
	 SECTION 10.5
	  	Subrogation	  	 	51	  
			
	 SECTION 10.6
	  	Relative Rights	  	 	51	  
			
	 SECTION 10.7
	  	Subordination May Not be Impaired by the Company	  	 	52	  
			
	 SECTION 10.8
	  	Distribution or Notice to the Representative	  	 	52	  
			
	 SECTION 10.9
	  	Rights of the Trustee	  	 	52	  
			
	 SECTION 10.10
	  	Authorization to Effect Subordination	  	 	53	  

							
			
	 SECTION 10.11
	  	Amendments	  	 	53	  
		
	 ARTICLE 11 PURCHASE OF SECURITIES UPON CVR FAILURE EVENT
	  	 	53	  
			
	 SECTION 11.1
	  	Notice of Trustee	  	 	53	  
			
	 SECTION 11.2
	  	Notice of Failure Purchase	  	 	53	  
			
	 SECTION 11.3
	  	Effect of Failure Purchase Notice	  	 	54	  
			
	 SECTION 11.4
	  	Deposit of Failure Purchase Price	  	 	54	  
			
	 SECTION 11.5
	  	Failure Purchase by the Company	  	 	55	  

 Annex A — Form of CVR Certificate/Global Security 

 

	Note:	  This table of contents shall not, for any purpose, be deemed to be a part of this CVR Agreement. 

 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of
[—] (this “CVR Agreement”), by and between Wright Medical Group, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company,
LLC, a New York limited liability trust company, as trustee (the “Trustee”), in favor of each person who from time to time holds one or more Contingent Value Rights (the “Securities” or “CVRs” and,
each individually, a “Security” or a “CVR”) to receive cash payments in the amounts and subject to the terms and conditions set forth herein. 
 W I T N E S S E T H: 
 WHEREAS, this CVR Agreement is entered into
pursuant to the Agreement and Plan of Merger, dated as of November 19, 2012 (the “Merger Agreement”), by and among the Company, Achilles Merger Subsidiary, Inc., a Delaware corporation and wholly owned Subsidiary of the Company
(“Merger Sub”), Achilles Acquisition Subsidiary, LLC, a Delaware limited liability company and a wholly owned Subsidiary of the Company, and BioMimetic Therapeutics, Inc., a Delaware corporation (“BioMimetic”);

 WHEREAS, pursuant to the Merger Agreement, BioMimetic shall merge with Merger Sub (the “Merger”);

 WHEREAS, the CVRs shall be issued in accordance with and pursuant to the terms of the Merger Agreement; and 

WHEREAS, a registration statement on Form S-4 (No. 333-XXXXXX) (the “Registration Statement”) with respect to the CVRs
has been prepared and filed by the Company with the Commission (as defined below) and has become effective in accordance with the Securities Act of 1933, as amended (the “Securities Act”). 

NOW, THEREFORE, in consideration of the foregoing premises and the consummation of the transactions contemplated by the Merger Agreement,
it is covenanted and agreed, for the equal and proportionate benefit of all Holders, as follows: 
 ARTICLE 1 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 
 SECTION 1.1 Definitions. For all purposes of this CVR Agreement, except as otherwise expressly provided or unless the context otherwise requires: 

(a) the terms defined in this ARTICLE 1 have the meanings assigned to them in this Article, and include the plural as well as the
singular; 
 (b) all accounting terms used herein and not expressly defined herein shall, except as otherwise noted, have the
meanings assigned to such terms in accordance with applicable Accounting Standards, where “Accounting Standards” means generally accepted accounting principals in the U.S., consistently applied, or, to the extent the Company adopts
International Financial Reporting Standards (“IFRS”), IFRS consistently applied; 

 (c) all capitalized terms used in this CVR Agreement without definition shall have the
respective meanings ascribed to them in the Merger Agreement; 
 (d) all other terms used herein which are defined in the Trust
Indenture Act (as defined herein), either directly or by reference therein, have the respective meanings assigned to them therein; and 
 (e) the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this CVR Agreement as a whole and not to any particular
Article, Section or other subdivision. 
 “BioMimetic” shall have the meaning set forth in the Recitals of this
CVR Agreement. 
 “Act” shall have the meaning set forth in SECTION 1.4(a) of this CVR Agreement. 

“Acting Holders” means, at the time of determination, Holders of at least thirty percent (30%) of the Outstanding
CVRs. 
 “Affiliate” of any specified Person means any other Person directly or indirectly controlling or
controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control” when used with respect to any specified Person means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

“Applicable Procedures” means, with respect to any transfer or exchange of or for beneficial interests in any Global
Security, the rules and procedures of the Depositary that apply to such transfer or exchange. 
 “Approval
Milestone” means receipt by the Company or one of its Affiliates of the first FDA Approval of AUGMENT Bone Graft based on the AUGMENT PMA. 
 “Approval Milestone Payment” means three dollars and fifty cents ($3.50) per CVR. 
 “Approval Milestone Payment Date” means, with respect to the Approval Milestone, either (i) the Closing Date, if such Milestone is achieved prior to the Closing Date, or
(ii) the date that is twenty (20) Business Days following the date of the achievement of such Milestone. 

“Approval Record Date” shall have the meaning set forth in SECTION 3.1(d) of this CVR Agreement. 

“AUGMATRIX Bone Graft” means that certain medical device that is described in the Company’s 510(k) No. 051775,
including any medical device that is sold by the Company, its Affiliates and/or licensees prior to the Termination Date outside the United States. 
 “AUGMENT Bone Graft” means that certain medical device that is described in the AUGMENT PMA, including any such medical device that is sold by the Company, its Affiliates and/or licensees
prior to the Termination Date outside the United States. 

  
 2 

 “AUGMENT Chronic Tendinopathy” means that certain medical device that is
described in the Company’s Investigational New Drug application No. 109460, as it may be further amended or supplemented, including any such medical device that is sold by the Company, its Affiliates and/or licensees prior to the
Termination Date outside the United States. 
 “AUGMENT Injectable” means that certain medical device that is
described in the Company’s Investigational Device Exemption application No. G090133, as it may be further amended or supplemented, including any such medical device that is sold by the Company, its Affiliates and/or licensees prior to the
Termination Date outside the United States. 
 “AUGMENT PMA” means the Company’s amended pre-market
approval application no. P100006 submitted to the FDA on June 28, 2012, as it may be further amended or supplemented prior to the Termination Date. 
 “Board of Directors” means the board of directors of the Company or any other body performing similar functions, or any duly authorized committee of that board. 

“Board Resolution” means a copy of a resolution certified by the Chairman of the Board of Directors, the Chief Executive
Officer of the Company or the Secretary to the Board of Directors, to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee. 

“Breach” shall have the meaning set forth in SECTION 8.1 of this CVR Agreement. 

“Breach Interest Rate” means a per annum rate equal to the prime rate of interest quoted by Bloomberg, or similar
reputable data source, plus three percent (3%), calculated daily on the basis of a three hundred sixty-five (365) day year or, if lower, the highest rate permitted under applicable Law. 

“Business Day” means any day (other than a Saturday or a Sunday) on which banking institutions in the city of New York,
New York are not authorized or obligated by Law or executive order to close and, if the CVRs are listed on a national securities exchange, electronic trading network or other suitable trading platform, such exchange, electronic network or other
trading platform is open for trading. 
 “Code” means the Internal Revenue Code of 1986, as amended.

 “Combination Product” means (1) any product comprised of a Product and any other drug, device, or
biologic (as each such term is defined by FDA or other relevant Governmental Entity) that is physically, chemically, or otherwise combined or mixed and produced as a single entity; or (2) a Product packaged with any other drug, device, or
biologic (as each such term is defined by FDA or other relevant Governmental Entity) and sold as a single unit for a single price. 
 “Commission” means the Securities and Exchange Commission, as from time to time constituted, created under the Exchange Act, or if at any time after the execution of this instrument such
Commission is not existing and performing the duties now assigned to it under the Trust Indenture Act, then the body performing such duties at such time. 

  
 3 

 “Company” means the Person named as the “Company” in the preamble
of this CVR Agreement, until a successor Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Company” shall mean such successor Person. 

“Company Request” or “Company Order” means a written request or order signed in the name of the Company
by the chairman of the Board of Directors, the Chief Executive Officer, a president or any vice president, or any other person duly authorized to act on behalf of the Company for such purpose or for any general purpose, and delivered to the Trustee.

 “Corporate Trust Office” means the office of the Trustee at which at any particular
time its corporate trust business shall be principally administered, which office at the date of execution of this CVR Agreement is located at 6201 15th Avenue, Brooklyn, New York 11219. 
 “CVRs” shall have the meaning set forth in the Preamble of this CVR Agreement. 
 “CVR Agreement” shall have the meaning set forth in the Preamble of this CVR Agreement. 
 “CVR Certificate” means a certificate other than a Global Security representing any of the CVRs. 
 “CVR Failure Date” means any date on which both of the following conditions are met: (a) the Approval Milestone has not been achieved and (b) the volume weighted
average price paid per Security for all Securities traded over the forty-five (45) trading days prior to such date is less than ten cents ($0.10).  
 “CVR Payment” means a Product Sales Milestone Payment or the Approval Milestone Payment. 
 “CVR Shortfall” shall have the meaning set forth in SECTION 7.6(b) of this CVR Agreement. 
 “Depositary” shall have the meaning set forth in SECTION 3.2 of this CVR Agreement. 
 “Diligent Efforts” means, with respect to any Product and subject to SECTION 7.9 below, efforts of a Person to carry out its obligations, using such efforts and employing such
resources normally used by Persons in the medical device business similar in size and resources to Parent, in the exercise of their reasonable business discretion, relating to development, seeking regulatory approval of or commercializing, as
applicable, a similar product, that is of similar market potential and at a similar development stage, regulatory stage or commercialization stage, taking into account issues of market exclusivity (including patent coverage), product profile,
including efficacy, safety, and convenience, actual product labeling, the competitiveness of alternate products in the marketplace or under development, the regulatory environment and the profitability of the applicable product (including pricing
and reimbursement status achieved) consistent with publicly reported financial statements and other relevant factors, including financial, technical, legal, scientific and/or medical factors. 

  
 4 

 “Direct Registration Securities” means Securities, the ownership of which
is recorded on the Direct Registration System. The terms “deliver,” “execute,” “issue,” “register,” “surrender,” “transfer” or “cancel,” when used with respect to Direct
Registration Securities, shall refer to an entry or entries or an electronic transfer or transfers in the Direct Registration System. 
 “Direct Registration System” means the system for the uncertificated registration of ownership of securities established by the Security Registrar and utilized by the Security Registrar
pursuant to which the Security Registrar may record the ownership of the CVRs without the issuance of a certificate, which ownership shall be evidenced by periodic statements issued by the Security Registrar to the Holders entitled thereto.

 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Exchange Act Documents” shall have the meaning set forth in SECTION 5.4 of this CVR Agreement. 

“Existing Licenses” means those licenses and related agreements (for so long as they are in effect) with respect to any
Product granted by or to BioMimetic or its Affiliates to or from third parties (other than the Company or its Affiliates) as in effect immediately prior to the consummation of the Merger. 

“Failure Purchase” shall have the meaning set forth in SECTION 11.1 of this CVR Agreement. 

“Failure Purchase Eligibility Date” means any CVR Failure Date that occurs on or after the third anniversary of Closing.

 “Failure Purchase Date” shall have the meaning set forth in SECTION 11.1 of this CVR Agreement.

 “Failure Purchase Notice” shall have the meaning set forth in SECTION 11.2 of this CVR Agreement.

 “Failure Purchase Offer” shall have the meaning set forth in SECTION 11.1 of this CVR Agreement.

 “Failure Purchase Price” shall have the meaning set forth in SECTION 11.5 of this CVR Agreement.

 “FDA” means the United States Food and Drug Administration or any successor agency. 

“FDA Approval” means the approval by the FDA of a premarket approval application to market and sell a Product, as
evidenced by the publication of such approval by the FDA. 
 “Global Securities” means global securities in
registered form, substantially in the form set forth in Annex A. 

  
 5 

 “Governmental Entity” means any domestic (federal or state), or foreign
court, commission, governmental body, regulatory or administrative agency or other political subdivision thereof. 

“Holder” means a Person in whose name a Security is registered in the Security Register. 

“IFRS” shall have the meaning set forth in SECTION 1.1(b) of this CVR Agreement. 

“Indemnitee” shall have the meaning set forth in SECTION 4.6(c) of this CVR Agreement. 

“Independent Accountant” shall have the meaning set forth in SECTION 7.6(a) of this CVR Agreement. 

“Indirect Participant” means a Person who holds a beneficial interest in a Global Security through a Participant.

 “Junior Obligations” shall have the meaning set forth in SECTION 10.1. 

“Law” means any foreign, federal, state, local or municipal laws, rules, judgments, orders, regulations, statutes,
ordinances, codes, decisions, injunctions, decrees, international treaties and conventions or requirements of any Governmental Entity. 
 “Marketed Product” means a Product: (a) that has received marketing approval in the applicable jurisdiction from the relevant Governmental Entity; and (b) for which commercial
sales have been initiated in such jurisdiction prior to the date of execution of this CVR Agreement or for which the Company and/or its Affiliates elect, in their sole discretion, to initiate commercial sales in such jurisdiction after the date of
execution of this CVR Agreement and prior to the Termination Date. 
 “Merger” shall have the meaning set forth
in the Recitals of this CVR Agreement. 
 “Merger Agreement” shall have the meaning set forth in the Recitals
of this CVR Agreement. 
 “Merger Sub” shall have the meaning set forth in the Recitals of this CVR Agreement.

 “Milestone” means any of the Approval Milestone or any Product Sales Milestone. 

“Officer’s Certificate” when used with respect to the Company means a certificate signed by the Chief Executive
Officer, a president or any vice president, the Chief Financial Officer or any other person duly authorized to act on behalf of the Company for such purpose or for any general purpose. 

“Opinion of Counsel” means a written opinion of counsel, who may be counsel for the Company. 

  
 6 

 “Outstanding” when used with respect to Securities (“Outstanding
Securities”) means, as of the date of determination, all Securities theretofore authenticated and delivered under this CVR Agreement, except: (a) Securities theretofore cancelled by the Trustee or delivered to the Trustee for
cancellation and (b) Securities in exchange for or in lieu of which other Securities have been authenticated and delivered pursuant to this CVR Agreement, other than any such Securities in respect of which there shall have been presented to the
Trustee proof satisfactory to it that such Securities are held by a bona fide purchaser in whose hands the Securities are valid obligations of the Company; provided, however, that in determining whether the Holders of the requisite
Outstanding Securities have given any request, demand, authorization, direction, consent, waiver or other action hereunder, Securities owned by the Company or any Affiliate of the Company, whether held as treasury securities or otherwise, shall be
disregarded and deemed not to be Outstanding, except that for the purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, consent, waiver or other action, only Securities that
a Responsible Officer of the Trustee actually knows are so owned shall be so disregarded (but the Trustee need not confirm or investigate the accuracy of mathematical calculations or other facts stated in such request, demand, authorization,
direction, consent, waiver or other action). 
 “Participant” means, with respect to the Depositary, a Person
who has an account with the Depositary. 
 “Party” shall mean the Trustee, the Company and/or Holder(s), as
applicable. 
 “Paying Agent” means any Person authorized by the Company to pay the amount determined pursuant
to SECTION 3.1 of this CVR Agreement, if any, on any Securities on behalf of the Company. 
 “Payment Date”
means a Product Sales Milestone Payment Date or the Approval Milestone Payment Date or any date as shall be required for any CVR Shortfall payment pursuant to the review procedure set forth in SECTION 7.6 of this CVR Agreement. 

“Permitted Junior Securities” shall have the meaning set forth in SECTION 10.2(a). 

“Person” means any individual, corporation, partnership, joint venture, association, joint­stock company, trust,
limited liability company, unincorporated organization or government or any agency or political subdivision thereof. 

“Product” means any of the following medical products: (a) AUGMENT Bone Graft; (b) AUGMENT Injectable;
(c) AUGMATRIX Bone Graft; (d) AUGMENT Chronic Tendinopathy; or (e) any other medical product that the Company, in its sole discretion, elects to offer for sale in any jurisdiction and that: (i) contains recombinant human
platelet-derived growth factor BB; and (ii) is covered by patents or utilizes proprietary know-how that was owned or controlled by Achilles immediately prior to the execution of this CVR Agreement.  

“Product Disposition Transaction” shall have the meaning set forth in SECTION 7.8 of this CVR Agreement. 

  
 7 

 “Product Sales” means: 

(a) the aggregate gross amounts invoiced for any Product sold by the Company, its Affiliates or licensees of the Company or its
Affiliates to third parties (other than the Company, its Affiliates or licensees of the Company and its Affiliates), including to distributors and end-users, less the following items (i) through (v) below as applicable to such Product
sales to the extent actually taken or incurred with respect to such sales ( “Permitted Deductions”) and all in accordance with standard allocation procedures, allowance methodologies and the Accounting Standards (except as otherwise
provided below): 
 (i) credits or allowances for returns, rejections or recalls (due to spoilage, damage, expiration of useful
life or otherwise), retroactive price reductions or billing corrections; 
 (ii) separately itemized invoiced freight, postage,
shipping and insurance, handling and other transportation costs; 
 (iii) sales, use, value added and other similar taxes
(excluding income taxes), tariffs, customs duties, surcharges and other governmental charges levied on the production, sale, transportation, delivery or use of any Product that are incurred at time of sale or are directly related to the sale;

 (iv) any quantity, cash or other trade discounts, rebates, returns, refunds, charge backs, fees, credits or allowances
(including amounts incurred in connection with government-mandated rebate and discount programs, third party rebates and charge backs, and hospital buying group/group purchasing organization administration fees and payor organizations), distribution
fees, sales commissions paid to third parties, retroactive price reductions and billing corrections (collectively, “Discounts”), excluding any discounts on Products that are not in the ordinary course of business of the Company, its
Affiliates or licensees, as applicable, that are offered solely to benefit the Company’s, or its applicable Affiliate’s or licensee’s, other products or services to the detriment of Product Sales or any discounts on Products that are
implemented in bad faith for the purpose of reducing Product Sales; and 
 (v) deductions for bad debts (which adjustment shall
be based on actual bad debts incurred, net of any recoveries of previously written off bad debts from current or prior reporting periods). 
 Sales or other commercial dispositions of any Product among the Company, its Affiliates and licensees of the Company or its Affiliates shall be excluded from the computation of Product Sales, except where
such an Affiliate or licensee is an end-user of such Product. Notwithstanding any other provision of this CVR Agreement, the following shall not be included in Product Sales: the use, transfer or other disposition of a Product at or below cost in
connection with research and/or development, clinical trials, compassionate use programs, for use as samples, or as donations to non-profit institutions or government agencies; provided that to the extent the Company is reimbursed by a
third-party payor for any of the foregoing, such reimbursements will be included in Product Sales. 

  
 8 

 Subject to the foregoing, if a Product is sold or otherwise commercially disposed of for
consideration other than cash or in a transaction that is not at arm’s-length between the buyer and the seller, then the gross amount to be included in the calculation of Product Sales shall be the amount that would have been invoiced had the
transaction been conducted at arm’s­length and for cash. Such amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling price of such Product in arm’s-length transactions during
the relevant calendar month and in the relevant jurisdiction. 
 Notwithstanding the foregoing, in the event that a Product is
sold as a Combination Product (a “Combination Sale”), the Product Sales amount for the Product sold in such a Combination Sale shall be determined as follows: 
 (i) By multiplying the gross amount invoiced for the Combination Sale (less all Permitted Deductions) by the fraction A/C where A is the average selling price charged by the Company, its Affiliates or
licensees of the Company or its Affiliates for such Product sold separately in such jurisdiction during such period, and C is the average selling price charged by the Company, its Affiliates or licensees of the Company or its Affiliates in such
jurisdiction for such Combination Product during such period. 
 (ii) In the event that the Company, its Affiliates or licensees
of the Company and its Affiliates do not sell during such period the Product included in a Combination Sale as a separate product in the jurisdiction where such Combination Sale occurs, but there are separate sales during such period of all of the
other products or active ingredients/components, as the case may be, included in the Combination Sale in such jurisdiction, the calculation of Product Sales resulting from such Combination Sale shall be determined by multiplying the gross amount
invoiced for the Combination Product (less all Permitted Deductions) by the fraction (C-D)/C, where C is the average selling price charged by the Company, its Affiliates or licensees of the Company or its Affiliates in such jurisdiction for such
Combination Product during such period, and D is the aggregate of the average selling price(s) charged by the Company, its Affiliates or licensees of the Company or its Affiliates, as applicable, in such jurisdiction, of such other product(s) or
active ingredients/components, as the case may be, included in the Combination Product and sold separately in such jurisdiction during such period. 
 If the calculation of Product Sales resulting from a Combination Sale in a jurisdiction cannot be determined by either of the foregoing methods, the calculation of Product Sales for such Combination Sale
shall be calculated in a manner determined by the Company in good faith based upon the relative value of the active components of such Combination Product. 
 “Product Sales Milestone” means each of (a) Product Sales Milestone #1 and (b) Product Sales Milestone #2. 

“Product Sales Milestone #1” means the first calendar month prior to the Termination Date in which the aggregate Product
Sales during the consecutive twelve (12) month period ending on the last day of such calendar month equals or exceeds a total of forty million dollars ($40,000,000). 

  
 9 

 “Product Sales Milestone #2” means the first calendar month prior to the
Termination Date in which the aggregate Product Sales during the consecutive twelve (12) month period ending on the last day of such calendar month equals or exceeds a total of seventy million dollars ($70,000,000), provided that Product
Sales that occur in a period or any portion thereof in which Product Sales Milestone #1 is achieved may be included in the calculation of Product Sales for determining whether Product Sales Milestone #2 has been achieved. 

“Product Sales Milestone Payment” means (a) one dollar and fifty cents ($1.50) per CVR with respect to achieving
Product Sales Milestone #1 and (b) one dollar and fifty cents ($1.50) per CVR with respect to achieving Product Sales Milestone #2. 
 “Product Sales Milestone Payment Date” means, with respect to each Product Sales Milestone, the date that is twenty (20) Business Days following notice of the achievement of such
Product Sales Milestone in the applicable Product Sales Statement; provided, however, (a) if Product Sales Milestone #1 is achieved during a consecutive twelve (12) month period that ends on the last day of a calendar month
that is prior to [            ][date that is 24 months post-closing to be inserted], then the Product Sales Milestone Payment Date for Product Sales Milestone #1 shall be on
the later of (i)                     or (ii) twenty (20) Business Days following notice of the achievement of Product Sales Milestone
#1, and (b) if Product Sales Milestone #2 is achieved during a consecutive twelve (12) month period that ends on the last day of a calendar month that is prior to
[                    ][date that is 36 months post-closing to be inserted], then the Product Sales Milestone Payment Date for Product
Sales Milestone #2 shall be the later of (i)             or (ii) twenty (20) Business Days following notice of the achievement of Product Sales Milestone #2. 

“Product Sales Statement” means, with respect to each calendar month (or part thereof) occurring prior to
the Termination Date, the written statement of the Company, certified by the Chief Financial Officer of the Company and setting forth with reasonable detail: 
 (a) the aggregate Product Sales during such calendar month and the eleven (11) immediately preceding calendar months; 
 (b) to the extent that Product Sales during an applicable period are determined based on Product Sales of a Combination Product for such period, the method of determining the Product Sales of the
Combination Product attributable to the Product in accordance with the definition of Product Sales; 
 (c) to the extent that
sales for a Product for an applicable period are recorded in currencies other than United States dollars, the exchange rates used for conversion of such foreign currency into United States dollars; and 

(d) notice of whether any Product Sales Milestone has been achieved during the applicable reporting period. 

The amounts in the Product Sales Statement shall be calculated in accordance with Accounting Standards and shall be derived from and
consistent with the audited financial statements contained in the reports filed with the Trustee pursuant to subsection (a)(i) or (a)(ii) of SECTION 5.4 of this CVR Agreement. 

  
 10 

 “PSM Record Date” shall have the meaning set forth in SECTION 3.1(c) of
this CVR Agreement. 
 “Registration Statement” shall have the meaning set forth in the Recitals of this CVR
Agreement. 
 “Responsible Officer” when used with respect to the Trustee means any officer assigned to the
Corporate Trust Office and also means, with respect to any particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his or her knowledge of and familiarity with the particular subject.

 “Securities” shall have the meaning set forth in the Preamble of this CVR Agreement. 

“Securities Act” shall have the meaning set forth in the Recitals of this CVR Agreement. 

“Security Register” shall have the meaning set forth in SECTION 3.4(a) of this CVR Agreement. 

“Security Registrar” shall have the meaning set forth in SECTION 3.4(a) of this CVR Agreement. 

“Senior Obligations” means the principal of, premium (if any), interest (including, without limitation, any interest
accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the documentation with respect thereto, whether or not such interest is an allowed claim under applicable Law) on the following existing or future obligations
of the Company, and all other amounts owing thereon, (i) with respect to borrowed money, (ii) evidenced by notes, debentures, bonds or other similar debt instruments, (iii) with respect to the net obligations owed under interest rate
swaps or similar agreements or currency exchange transactions, (iv) reimbursement obligations in respect of letters of credit and similar obligations, (v) in respect of capital leases, or (vi) guarantees in respect of obligations
referred to in clauses (i) through (v) above; unless, in any case, the instrument creating or evidencing the same or pursuant to which the same is outstanding provides that such obligations are pari passu to or subordinate in right of
payment to the Securities. 
 Notwithstanding the foregoing, “Senior Obligations” shall not include: 

(a) Junior Obligations (as defined in SECTION 10.1); 
 (b) trade debt incurred in the ordinary course of business; 
 (c) any intercompany
indebtedness between the Company and any of its Subsidiaries or Affiliates; 
 (d) indebtedness of the Company that is
subordinated in right of payment to Senior Obligations; 

  
 11 

 (e) indebtedness or other obligations of the Company that by its terms ranks equal or junior
in right of payment to the Junior Obligations; 
 (f) indebtedness of the Company that, by operation of Law, is subordinate to
any general unsecured obligations of the Company; 
 (f) indebtedness evidenced by any guarantee of indebtedness ranking equal
or junior in right of payment to the Junior Obligations; 
 (g) indebtedness consisting of the deferred purchase price for
property or services, including earn-out and milestone payments and contingent value rights; or 
 (h) indebtedness that is
contractually non-recourse to the general credit of the Company. 
 “Series A Contingent Value Rights” shall
have the meaning set forth in SECTION 3.1(b) of this CVR Agreement. 
 “Shortfall Interest Rate” means a per
annum rate equal to the prime rate of interest quoted by Bloomberg, or similar reputable data source, plus two percent (2%), calculated daily on the basis of a three hundred sixty-five (365) day year or, if lower, the highest rate permitted
under applicable Law. 
 “Shortfall Report” shall have the meaning set forth in SECTION 7.6(b) of this CVR
Agreement. 
 “Subsidiary” means, with respect to any Person, any corporation, limited liability company,
association, partnership or other business entity of which more than fifty percent (50%) of the total voting power of shares of Voting Securities is at the time owned or controlled, directly or indirectly, by: (a) such Person;
(b) such Person and one or more Subsidiaries of such Person; or (c) one or more Subsidiaries of such Person. 

“Tax” means any federal, state, local or foreign income, profits, gross receipts, license, payroll, employment,
severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock, franchise, sales, social security, unemployment, disability, use, property, withholding, excise, transfer, registration, production, value added,
alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the imposition of any such tax, whether disputed or not.

 “Termination Date” means the earlier of
(a)                     [6th anniversary of closing date of Merger Agreement to be inserted] and (b) the Payment Date for Product Sales Milestone #2. 

“Trust Indenture Act” means the Trust Indenture Act of 1939, as amended from time to time. 

  
 12 

 “Trustee” means the Person named as the “Trustee” in the preamble
of this CVR Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Trustee” shall mean such successor Trustee. 

“Voting Securities” means securities or other interests having voting power, or the right, to elect or appoint a
majority of the directors, or any Persons performing similar functions, irrespective of whether or not stock or other interests of any other class or classes shall have or might have voting power or any right by reason of the happening of any
contingency. 
 SECTION 1.2 Compliance and Opinions. 

(a) Upon any application or request by the Company to the Trustee to take any action under any provision of this CVR Agreement, the
Company shall furnish to the Trustee an Officer’s Certificate stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied with and an
Opinion of Counsel stating, subject to customary exceptions, that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that, in the case of any such application or request as to which the furnishing
of such documents is specifically required by any provision of this CVR Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. 

(b) Every certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR Agreement shall
include: (i) a statement that each individual signing such certificate or opinion has read such covenant or condition and the definitions herein relating thereto; (ii) a brief statement as to the nature and scope of the examination or
investigation upon which the statements or opinions contained in such certificate or opinion are based; (iii) a statement that, in the opinion of each such individual, he or she has made such examination or investigation as is necessary to
enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to whether, in the opinion of each such individual, such condition or covenant has been complied
with. 
 SECTION 1.3 Form of Documents Delivered to Trustee. 

(a) In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person, it is not
necessary that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion with respect to some matters and
one or more other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. 
 (b) Any certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a certificate or opinion of, or representations by, counsel. Any such certificate or
Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the Company stating that the information with respect to such factual matters is in the
possession of the Company. 

  
 13 

 (c) Any certificate, statement or opinion of an officer of the Company or of counsel may be
based, insofar as it relates to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Company. Any certificate or opinion of any independent firm of public accountants
filed with the Trustee shall contain a statement that such firm is independent. 
 (d) Where any Person is required to make,
give or execute two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument. 

SECTION 1.4 Acts of Holders. 
 (a) Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement to be given or taken by Holders may be embodied in and evidenced by one or more
instruments of substantially similar tenor signed by such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall become effective when such instrument or instruments are
delivered to the Trustee and, where it is hereby expressly required, to the Company. Such instrument or instruments (and the action embodied therein and evidenced thereby) are herein sometimes referred to as the “Act” of the Holders
signing such instrument or instruments. Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR Agreement and (subject to SECTION 4.1) conclusive in favor of the Trustee and
the Company, if made in the manner provided in this SECTION 1.4. The Company may set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this
CVR Agreement, which date shall be no greater than ninety (90) days and no less than ten (10) days prior to the date of such vote or consent to any action by vote or consent authorized or permitted under this CVR Agreement. If not
previously set by the Company, (i) the record date for determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding the date notice of such meeting is mailed to the Holders, or if notice is not given, on the
day next preceding the day such meeting is held, and (ii) the record date for determining the Holders entitled to consent to any action in writing without a meeting shall be the first date on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the Company. If a record date is fixed, those Persons who were Holders of Securities at such record date (or their duly designated proxies), and only those Persons, shall be entitled to take such
action by vote or consent or, except with respect to clause (d) below, to revoke any vote or consent previously given, whether or not such Persons continue to be Holders after such record date. No such vote or consent shall be valid or
effective for more than one hundred twenty (120) days after such record date. 
 (b) The fact and date of the execution by
any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient. 

  
 14 

 (c) The ownership of Securities shall be proved by the Security Register. Neither the
Company nor the Trustee nor any agent of the Company or the Trustee shall be affected by any notice to the contrary. 
 (d) At
any time prior to (but not after) the evidencing to the Trustee, as provided in this SECTION 1.4, of the taking of any action by the Holders of the Securities specified in this CVR Agreement in connection with such action, any Holder of a Security
the serial number of which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as
provided in this SECTION 1.4, revoke such action so far as concerns such Security. Any request, demand, authorization, direction, notice, consent, waiver or other action by the Holder of any Security shall bind every future Holder of the same
Security or the Holder of every Security issued upon the registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying Agent or the Company in
reliance thereon, whether or not notation of such action is made upon such Security. 
 SECTION 1.5 Notices, etc., to Trustee
and Company. Any request, demand, authorization, direction, notice, consent, waiver or Act of Holders or other document provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with: 

(a) the Trustee by any Holder or by the Company shall be sufficient for every purpose hereunder if made, given, furnished or filed, in
writing, to or with the Trustee at its Corporate Trust Office; or 
 (b) the Company by the Trustee or by any Holder shall be
sufficient for every purpose hereunder if in writing and mailed, first-class postage prepaid, to the Company addressed to it at Wright Medical Group, Inc., 5677 Airline Road, Arlington, Tennessee 38002, Attention: General Counsel, or at any other
address previously furnished in writing to the Trustee by the Company. 
 SECTION 1.6 Notice to Holders; Waiver.

 (a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless
otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder’s address as it appears in the Security Register, not later than the latest date, and not earlier
than the earliest date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the
sufficiency of such notice with respect to other Holders. Where this CVR Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such
waiver shall be the equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. 

  
 15 

 (b) In case by reason of the suspension of regular mail service or by reason of any other
cause, it shall be impracticable to mail notice of any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice.

 SECTION 1.7 Conflict with Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with another
provision hereof which is required to be included in this CVR Agreement by any of the provisions of the Trust Indenture Act, such required provision shall control. Nothing herein shall be deemed an admission of, or agreement by, the Company and the
Trustee that the Trust Indenture Act applies to this CVR Agreement. 
 SECTION 1.8 Effect of Headings and Table of
Contents. The Article and Section headings herein and the Table of Contents are for convenience only and shall not affect the construction hereof. 
 SECTION 1.9 Benefits of Agreement. Nothing in this CVR Agreement or in the Securities, express or implied, shall give to any Person (other than the Parties hereto and their successors hereunder,
any Paying Agent and the Holders) any benefit or any legal or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained, all such covenants and provisions being for sole benefit of the Parties
hereto and their successors, any Paying Agent and of the Holders. 
 SECTION 1.10 Governing Law. THIS CVR AGREEMENT AND
ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON,
ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS CVR AGREEMENT OR AS AN INDUCEMENT TO ENTER INTO THIS CVR AGREEMENT) OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY STATE
COURT IN THE STATE OF DELAWARE OR THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RESPECT OF ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR AGREEMENT, OR THE
NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, 

  
 16 

 
ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS CVR AGREEMENT OR AS AN INDUCEMENT TO ENTER INTO THIS CVR AGREEMENT), OR THE SECURITIES, AND
IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT PROCESS MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE LAWS
OF THE STATE OF DELAWARE FOR SUCH PERSONS. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT, BY WAY OF MOTION, AS A DEFENSE, COUNTERCLAIM OR OTHERWISE, IN ANY ACTION OR PROCEEDING WITH RESPECT TO THIS CVR
AGREEMENT (A) THE DEFENSE OF SOVEREIGN IMMUNITY, (B) ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF THE ABOVE-NAMED COURTS FOR ANY REASON OTHER THAN THE FAILURE TO SERVE PROCESS IN ACCORDANCE WITH THIS
SECTION 1.10, (C) THAT IT OR ITS PROPERTY IS EXEMPT OR IMMUNE FROM JURISDICTION OF ANY SUCH COURT OR FROM ANY LEGAL PROCESS COMMENCED IN SUCH COURTS (WHETHER THROUGH SERVICE OF NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF
EXECUTION OF JUDGMENT, EXECUTION OF JUDGMENT OR OTHERWISE), AND (D) TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT (I) THE SUIT, ACTION OR PROCEEDING IN SUCH COURT IS BROUGHT IN AN INCONVENIENT FORUM, (II) THE VENUE OF SUCH SUIT,
ACTION OR PROCEEDING IS IMPROPER AND (III) THIS CVR AGREEMENT, OR THE SUBJECT MATTER HEREOF, MAY NOT BE ENFORCED IN OR BY SUCH COURTS. 
 SECTION 1.11 Legal Holidays. In the event that a Payment Date shall not be a Business Day, then (notwithstanding any provision of this CVR Agreement or the Securities to the contrary) payment on
the Securities need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with the same force and effect as if made on such Payment Date. 

SECTION 1.12 Separability Clause. In the event any provision in this CVR Agreement or in the CVRs shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 SECTION 1.13 No Recourse Against Others. A director, officer or employee, as such, of the Company or an Affiliate of the Company or the Trustee shall not have any liability for any obligations of
the Company or the Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Security each Holder waives and releases all such liability. The waiver
and release are part of the consideration for the issue of the Securities. 
 SECTION 1.14 Counterparts. This CVR
Agreement shall be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this CVR Agreement. 

  
 17 

 SECTION 1.15 Acceptance of Trust. American Stock Transfer & Trust Company,
LLC, the Trustee named herein, hereby accepts the trusts in this CVR Agreement declared and provided, upon the terms and conditions set forth herein. 
 SECTION 1.16 Termination. This CVR Agreement shall terminate and be of no further force or effect, and the parties hereto shall have no liability hereunder, at 5:00 p.m., New York City time, on the
Termination Date, provided that if any Milestone has been achieved on or prior to the Termination Date, but the associated CVR Payment has not been paid on or prior to the Termination Date, this CVR Agreement shall not terminate until such
CVR Payment has been paid in full in accordance with the terms of the CVR Agreement; provided further that the obligations of the Parties to this CVR Agreement set forth in SECTIONS 4.6 and 7.6 and the obligation of the Company to pay
any CVR Payment that is due in accordance with the terms of this CVR Agreement shall survive termination of this CVR Agreement in accordance with its terms and provided further that no termination of this CVR Agreement shall be deemed
to affect the rights of the parties set forth in ARTICLE 8 to bring suit in the case of a Breach occurring prior to such Termination Date. 
 ARTICLE 2 
 SECURITY FORMS 

SECTION 2.1 Forms Generally. 
 (a) The Global Securities, CVR Certificates, if any, and the Trustee’s certificate of authentication shall be in substantially the forms set forth in Annex A, attached hereto and incorporated
herein by this reference, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such letters, numbers or other marks of identification and such legends or
endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or regulation pursuant thereto, all as may be determined by the officers executing such Global Securities or
CVR Certificates, as evidenced by their execution of the Global Securities or CVR Certificates. Any portion of the text of any Global Security or CVR Certificate may be set forth on the reverse thereof, with an appropriate reference thereto on the
face of the Global Security or CVR Certificate. 
 (b) The Global Securities and CVR Certificates, if any, shall be typewritten,
printed, lithographed or engraved on steel engraved borders or produced by any combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the Securities may be listed, all as
determined by the officers executing such Securities, as evidenced by their execution of such Securities. 

  
 18 

 (c) The Direct Registration Securities shall be uncertificated and shall be evidenced by the
Direct Registration System maintained by the Security Registrar. 
 ARTICLE 3 

THE SECURITIES 

SECTION 3.1 Title and Payment Terms. 
 (a) The aggregate number of CVRs which may be authenticated, as applicable, and delivered under this CVR Agreement is limited to a number equal to [—],
except for Securities authenticated, as applicable, and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities pursuant to SECTION 3.4, 3.5 or 6.6. From and after the Effective Time, the Company shall not be
permitted to issue any CVRs that have the right to receive any portion of the Approval Milestone Payment or the Product Sales Milestone Payments, except as provided and in accordance with the terms and conditions of the Merger Agreement. 

(b) The Securities shall be known and designated as the “Series A Contingent Value Rights” of the Company. 

(c) On each Product Sales Milestone Payment Date, the Company shall pay to the Trustee, by wire transfer to the account designated by the
Trustee on the date hereof, an amount equal to the product of (i) the Product Sales Milestone Payment due on such Product Sales Milestone Payment Date multiplied by (ii) the number of Securities Outstanding, and the Trustee shall promptly
(but in any event within two (2) Business Days) pay to each Holder of record of the Securities as of the close of business in New York City, three (3) Business Days prior to such Product Sales Milestone Payment Date (a “PSM Record
Date”), an amount equal to the product of (i) such Product Sales Milestone Payment multiplied by (ii) the number of Securities held by such Holder as of such PSM Record Date. Notwithstanding the foregoing, in no event shall the
Company be required to pay a Product Sales Milestone Payment more than once in relation to any particular Product Sales Milestone, and the Company shall not be required to pay any Product Sales Milestone Payment in relation to a Product Sales
Milestone that is achieved after the Termination Date. 
 (d) On the Approval Milestone Payment Date, the Company shall pay to
the Trustee, by wire transfer to the account designated by the Trustee on the date hereof, an amount equal to the product of (i) the Approval Milestone Payment multiplied by (ii) the number of Securities Outstanding, and the Trustee shall
promptly (but in any event within two (2) Business Days) pay to each Holder of record of the Securities as of the close of business in New York City, three (3) Business Days prior to the Approval Milestone Payment Date (the
“Approval Record Date”), an amount equal to the product of (i) the Approval Milestone Payment multiplied by (ii) the number of Securities held by such Holder as of the Approval Record Date. Notwithstanding the foregoing,
in no event shall the Company be required to pay the Approval Milestone Payment more than once, and the Company shall not be required to pay the Approval Milestone Payment if: (i) the FDA issue an order under 21 CFR 814.45 denying FDA Approval
of Augment; or (ii) the Approval Milestone occurs after the Termination Date. For the avoidance of doubt, FDA Approval of anything other than the AUGMENT PMA shall not trigger the Approval Milestone Payment. 

  
 19 

 (e) The Holders of the CVRs, by acceptance thereof, agree that no joint venture, partnership
or other fiduciary relationship is created hereby or by the Securities. 
 (f) Other than in the case of interest on amounts due
and payable after the occurrence of a Breach or with respect to any CVR Shortfall, no interest or dividends shall accrue on any amounts payable in respect of the CVRs. 
 (g) Except to the extent otherwise required pursuant to a “determination” within the meaning of Section 1313(a) of the Code, the Parties hereto shall determine the portion of any CVR
Payment required to be treated as interest for U.S. federal income tax purposes pursuant to Section 483 of the Code and the Treasury Regulations promulgated thereunder. 
 (h) The Holder of any CVR is not, and shall not, by virtue thereof, be entitled to any rights of a holder of any Voting Securities or other equity security or other ownership interest of the Company, in
any constituent company to the Merger or in any of such companies’ Affiliates or other subsidiaries, either at Law or in equity, and the rights of the Holders are limited to those contractual rights expressed in this CVR Agreement. 

(i) Except as provided in this CVR Agreement (including, without limitation, SECTION 7.6), none of the Company or any of its Affiliates
shall have any right to set off any amounts owed or claimed to be owed by any Holder to any of them against such Holder’s Securities or any CVR Payment or other amount payable to such Holder in respect of such Securities. 

(j) In the event that all of the CVRs not previously cancelled shall have become due and payable pursuant to the terms hereof, all
disputes with respect to amounts payable to the Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and the Company has paid or caused to be paid or deposited with the Trustee all amounts payable to the
Holders under this CVR Agreement (including any amounts determined in accordance with SECTION 7.6), then this CVR Agreement shall cease to be of further effect and shall be deemed satisfied and discharged. Notwithstanding the satisfaction and
discharge of this CVR Agreement, the obligations of the Company under SECTION 4.6(c) shall survive. 
 SECTION 3.2
Registrable Form. The Securities shall be issuable only in registered form. The CVRs shall be issued initially in the form of (a) one or more permanent Global Securities, deposited with the Trustee, as the custodian for The Depository
Trust Company, its nominees and successors (the “Depositary”), or (b) one or more Direct Registration Securities. Each Global Security will represent such of the Outstanding Securities as will be specified therein and each
shall provide that it represents the aggregate number of Outstanding Securities from time to time endorsed thereon and that the aggregate number of Outstanding Securities represented thereby may from time to time be reduced or increased, as
appropriate to reflect exchanges. 

  
 20 

 SECTION 3.3 Execution, Authentication, Delivery and Dating. 

(a) The Global Securities and CVR Certificates, if any, shall be executed on behalf of the Company by its Chief Executive Officer or any
other person duly authorized to act on behalf of the Company for such purpose or any general purpose, but need not be attested. The signature of any of these persons on the Global Securities or CVR Certificates, if any, may be manual or facsimile.

 (b) Securities bearing the manual or facsimile signatures of individuals who were, at the time of execution, the proper
officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and delivery of such Securities or did not hold such offices at the date of such
Securities. 
 (c) At any time and from time to time after the execution and delivery of this CVR Agreement, the Company may
deliver a Company Order for the authentication, as applicable, and delivery of Securities; and the Trustee, in accordance with such Company Order, shall authenticate and deliver such Securities as provided in this CVR Agreement and not otherwise. In
the case of Global Securities or CVR Certificates, such Company Order shall be accompanied by Global Securities or CVR Certificates executed by the Company and delivered to the Trustee for authentication in accordance with such Company Order.

 (d) Each Global Security or CVR Certificate shall be dated the date of its authentication. 

(e) No Global Security or CVR Certificate shall be entitled to any benefit under this CVR Agreement or be valid or obligatory for any
purpose unless there appears on such Security a certificate of authentication substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile signature of an authorized officer, and such certificate upon any
Security shall be conclusive evidence, and the only evidence, that such Global Security or CVR Certificate has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this CVR Agreement. 

(f) Direct Registration Securities need not be authenticated, and shall be valid and obligatory for all purposes and shall entitle each
Holder thereof to all benefits of this CVR Agreement. 
 SECTION 3.4 Registration, Registration of Transfer and Exchange.

 (a) The Company shall cause to be kept at the office of the Trustee a register (the register maintained in such office and in
any other office or agency designated pursuant to SECTION 7.2 being herein sometimes referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the
registration of Securities and of transfers of Securities. The Trustee is hereby initially appointed “Security Registrar” for the purpose of registering Securities and transfers of Securities as herein provided. 

  
 21 

 (b) (i) Upon surrender for registration of transfer of any CVR Certificate at the office or
agency of the Company designated pursuant to SECTION 7.2, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new CVR Certificates, or at the Company’s
election, deliver evidence of b Direct Registration Securities, representing the same aggregate number of CVRs represented by the CVR Certificate so surrendered that are to be transferred and the Company shall execute and the Trustee shall
authenticate and deliver, in the name of the transferor, one or more new CVR Certificates, or at the Company’s election, deliver evidence of direct registration of CVRs, representing the aggregate number of CVRs represented by such CVR
Certificate that are not to be transferred; 
 (i) A Global Security may not be transferred except as a whole by
the Depositary to a nominee of the Depositary, by a nominee of the Depositary to the Depositary or to another nominee of the Depositary, or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary.
All Global Securities will be exchanged by the Company for Direct Registration Securities if (1) the Company delivers to the Security Registrar notice from the Depositary that it is unwilling or unable to continue to act as Depositary or that
it is no longer a clearing agency registered under the Exchange Act and, in either case, a successor Depositary is not appointed by the Company within 120 days after the date of such notice from the Depositary; (2) the Company in its sole
discretion determines that the Global Securities (in whole but not in part) should be exchanged for Direct Registration Securities and delivers a written notice to such effect to the Security Registrar or (3) a Breach has occurred and is
continuing and the Security Registrar has received a request from the Depositary to issue Direct Registration Securities. Upon the occurrence of either of the preceding events in (1) or (2) above, Direct Registration Securities shall be
issued in such names as the Depositary shall instruct the Trustee. Global Securities also may be exchanged or replaced, in whole or in part, as provided in SECTION 3.5 hereof. Every Global Security authenticated and delivered in exchange for, or in
lieu of, a Global Security or any portion thereof, pursuant to this SECTION 3.4 or SECTION 3.5 hereof, shall be authenticated and delivered in the form of, and shall be, a Global Security. A Global Security may not be exchanged for another Global
Security other than as provided in this SECTION 3.4(b)(i), however, beneficial interests in a Global Security may be transferred and exchanged as provided in SECTION 3.4(b)(iii) or (iv) hereof. 

(ii) At the option of the Holder, CVR Certificates may be exchanged for other CVR Certificates that represent in the
aggregate the same number of CVRs as the CVR Certificates surrendered at such office or agency. Whenever any CVR Certificates are so surrendered for exchange, the Company shall execute and the Trustee shall authenticate and deliver, the CVR
Certificates which the Holder making the exchange is entitled to receive. 
 (iii) The transfer and exchange of
beneficial interests in the Global Securities will be effected through the Depositary, in accordance with the provisions of this CVR 

  
 22 

 
Agreement and the Applicable Procedures. Beneficial interests in any Global Security may be transferred to Persons who take delivery thereof in the form of a beneficial interest in Global
Security. No written orders or instructions shall be required to be delivered to the Security Registrar to effect the transfers described in this SECTION 3.4(b)(iii). 

(iv) If any holder of a beneficial interest in a Global Security proposes to exchange such beneficial interest for a
Direct Registration Security or to transfer such beneficial interest to a Person who takes delivery thereof in the form of a Direct Registration Security, then the Security Registrar will cause the aggregate number of CVRs represented by the
applicable Global Security to be reduced accordingly pursuant to SECTION 3.4(b)(vii) hereof, and the Security Registrar will deliver to the Person designated in the instructions a Direct Registration Security in the appropriate number of CVRs. Any
Direct Registration Security issued in exchange for a beneficial interest pursuant to this SECTION 3.4(b)(iv) will be registered in such name or names and in such authorized denomination or denominations as the holder of such beneficial interest
requests through instructions to the Security Registrar from or through the Depositary and the Participant or Indirect Participant. 
 (v) A Holder of a Direct Registration Security may exchange such Direct Registration Security for a beneficial interest in a Global Security or transfer such Direct Registration Security to a Person who
takes delivery thereof in the form of a beneficial interest in a Global Security at any time. Upon receipt of a request for such an exchange or transfer, the Security Registrar will cancel the applicable Direct Registration Security and increase or
cause to be increased the aggregate number of CVRs represented by one of the Global Securities. 
 (vi) Upon
request by a Holder of Direct Registration Securities and such Holder’s compliance with the provisions of this SECTION 3.4(b)(vi), the Security Registrar will register the transfer or exchange of Direct Registration Securities. Prior to such
registration of transfer or exchange, the requesting Holder must present to the Security Registrar a written instruction of transfer in form satisfactory to the Security Registrar duly executed by such Holder or by its attorney, duly authorized in
writing. A Holder of Direct Registration Securities may transfer such Direct Registration Securities to a Person who takes delivery thereof in the form of Direct Registration Securities. Upon receipt of a request to register such a transfer, the
Security Registrar shall register the Direct Registration Securities pursuant to the instructions from the Holder thereof. 
 (vii) At such time as all beneficial interests in a particular Global Security have been exchanged for Direct Registration Securities or a particular Global Security has been repurchased or canceled in
whole and not in part, each such Global Security will be returned to or retained and canceled by the Security Registrar in accordance with SECTION 3.8 hereof. At any time prior to such cancellation, if any beneficial interest in a Global Security is
exchanged for or transferred to a Person who will take delivery thereof in the form of a beneficial interest in another Global Security or for Direct Registration Securities, the aggregate number of CVRs represented by such Global Security will be
reduced accordingly and an endorsement will be made on such Global 

  
 23 

 
Security by the Security Registrar or by the Depositary at the direction of the Security Registrar to reflect such reduction; and if the beneficial interest is being exchanged for or transferred
to a Person who will take delivery thereof in the form of a beneficial interest in another Global Security, such other Global Security will be increased accordingly and an endorsement will be made on such Global Security by the Security Registrar or
by the Depositary at the direction of the Security Registrar to reflect such increase. 
 (viii) (A) To
permit registrations of transfers and exchanges, the Company will execute and the Trustee will authenticate Global Securities upon receipt of a Company Order in accordance with SECTION 3.3 hereof or at the Security Registrar’s request.

 (B) No service charge will be made to a Holder of a beneficial interest in a Global Security or to a Holder of
a Direct Registration Security for any registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith. 

(C) All Global Securities and Direct Registration Securities issued upon any registration of transfer or exchange of
Global Securities or Direct Registration Securities will be the valid obligations of the Company, evidencing the same rights, and entitled to the same benefits under this CVR Agreement, as the Global Securities or Direct Registration Securities
surrendered upon such registration of transfer or exchange. 
 (D) The Trustee will authenticate Global
Securities and CVR Certificates in accordance with the provisions of SECTION 3.3 hereof. 
 SECTION 3.5 Mutilated, Destroyed,
Lost and Stolen Securities. 
 (a) If (i) any mutilated Global Security or CVR Certificate is surrendered to the
Trustee, or (ii) the Company and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Global Security or CVR Certificate, and there is delivered to the Company and the Trustee (A) such security or
indemnity as may be reasonably required by them to save each of them and any agent of either harmless and (B) an affidavit of loss in respect of such Security, then, in the absence of notice to the Company or the Trustee that such Global
Security or CVR Certificate has been acquired by a bona fide purchaser, the Company shall execute and, upon delivery of a Company Order, the Trustee shall authenticate, as applicable, and deliver, in exchange for any such mutilated Global Security
or CVR Certificate or in lieu of any such destroyed, lost or stolen Security, a new CVR, in the form of either a Global Security, a CVR Certificate or a Direct Registration Security, of like tenor and amount of CVRs, bearing a number not
contemporaneously outstanding. 
 (b) In case any such mutilated, destroyed, lost or stolen Global Security or CVR Certificate
has become or is to become finally due and payable within fifteen (15) days, the Company in its discretion may, instead of issuing a new CVR, pay to the Holder of such Security on the applicable Payment Date, as the case may be, all amounts due
and payable with respect thereto. 

  
 24 

 (c) Every new Security issued pursuant to this SECTION 3.5 in lieu of any destroyed, lost or
stolen Global Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR
Agreement equally and proportionately with any and all other Securities duly issued hereunder. 
 (d) The provisions of this
SECTION 3.5 are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. 

SECTION 3.6 Payments with Respect to CVRs. Payment of any amounts pursuant to the CVRs shall be made in such coin or currency of
the United States of America as at the time is legal tender for the payment of public and private debts. The Company may, at its option, pay such amounts by wire transfer or check payable in such money. 

SECTION 3.7 Persons Deemed Owners. Prior to the time of due presentment for registration of transfer, the Company, the Trustee and
any agent of the Company or the Trustee may treat the Person in whose name any Security is registered as the owner of such Security for the purpose of receiving payment on such Security and for all other purposes whatsoever, whether or not such
Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 
 SECTION 3.8 Cancellation. All Securities surrendered for payment, registration of transfer or exchange shall, if surrendered to any Person other than the Trustee, be delivered to the Trustee and
shall be promptly cancelled by it. The Company shall promptly deliver to the Trustee for cancellation any Securities previously authenticated and delivered hereunder which the Company has acquired in any manner whatsoever, and all Securities so
delivered shall be promptly cancelled by the Trustee. No Securities shall be authenticated in lieu of or in exchange for any Securities cancelled as provided in this SECTION 3.8, except as expressly permitted by this CVR Agreement. All cancelled
Securities held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to the Company, unless otherwise directed by a Company Order. 
 SECTION 3.9 CUSIP Numbers. The Company in issuing the Securities may use “CUSIP” numbers (if then generally in use). The Company shall promptly notify the Trustee in writing of any change
in the “CUSIP” numbers. 

  
 25 

 ARTICLE 4 
 THE TRUSTEE 
 SECTION 4.1 Certain Duties and Responsibilities. 

(a) With respect to the Holders, the Trustee, prior to the occurrence of a Breach (as defined in SECTION 8.1) with respect to the
Securities and after the curing or waiving of all Breaches which may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR
Agreement against the Trustee. In case a Breach with respect to the Securities has occurred (which has not been cured or waived), the Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of
care and skill in their exercise, as a reasonably prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. 
 (b) In the absence of bad faith on its part, prior to the occurrence of a Breach and after the curing or waiving of all such Breaches which may have occurred, the Trustee may conclusively rely, as to the
truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee which conform to the requirements of this CVR Agreement; but in the case of any such certificates or opinions which
by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this CVR Agreement. 

(c) No provision of this CVR Agreement shall be construed to relieve the Trustee from liability for its own negligent action, its own
negligent failure to act, or its own willful misconduct, except that (i) this Subsection (c) shall not be construed to limit the effect of Subsections (a) and (b) of this SECTION 4.1; (ii) the Trustee shall not be liable for
any error of judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and (iii) the Trustee shall not be liable with respect to any action taken or
omitted to be taken by it in good faith in accordance with the direction of the Holders pursuant to SECTION 8.9 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or
power conferred upon the Trustee, under this CVR Agreement. 
 (d) Whether or not therein expressly so provided, every provision
of this CVR Agreement relating to the conduct or affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this SECTION 4.1. 

  
 26 

 SECTION 4.2 Certain Rights of Trustee. Subject to the provisions of SECTION 4.1,
including without limitation, the duty of care that the Trustee is required to exercise upon the occurrence of a Breach: 
 (a)
the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of
indebtedness or other paper or document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties and the Trustee need not investigate any fact or matter stated in the document; 

(b) any request or direction or order of the Company mentioned herein shall be sufficiently evidenced by a Company Request or Company
Order and any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it takes or omits to take in good faith reliance thereon; 

(c) whenever in the administration of this CVR Agreement the Trustee shall deem it desirable that a matter be proved or established prior
to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, rely upon an Officers’ Certificate and the Trustee shall not be liable
for any action it takes or omits to take in good faith reliance thereon or an Opinion of Counsel; 
 (d) the Trustee may consult
with counsel and the written advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such
advice or Opinion of Counsel; 
 (e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in
it by this CVR Agreement at the request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might
be incurred by it in compliance with such request or direction; 
 (f) the Trustee shall not be bound to make any investigation
into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document, but the Trustee in
its discretion may make such further inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and
premises of the Company, personally or by agent or attorney, as necessary for such inquiry or investigation at the sole cost of the Company and shall incur no liability of any kind by reason of such inquiry or investigation other than as a result of
Trustee’s gross negligence or willful misconduct; 
 (g) the Trustee may execute any of the trusts or powers hereunder or
perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder; 

(h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good faith and believed by it to be
authorized or within the discretion or rights or powers conferred upon it by this CVR Agreement; 

  
 27 

 (i) the rights, privileges, protections, immunities and benefits given to the Trustee,
including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Paying Agent, the Security Registrar, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed
to act hereunder; 
 (j) in no event shall the Trustee be responsible or liable for special, indirect, or consequential loss or
damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action; 

(k) certain of the Trustee’s duties hereunder may be performed by the Paying Agent or Security Registrar; 

(l) the Trustee shall not be deemed to have knowledge of any Breach except any Breach of which the Trustee shall have received written
notification or otherwise obtained actual knowledge. In the absence of such notice, the Trustee may conclusively assume there is no Breach except as aforesaid; 
 (m) the Trustee shall not be required to give any bond or surety in respect of the performance of its powers and duties hereunder; 
 (n) the permissive rights of the Trustee enumerated in this CVR Agreement shall not be construed as duties hereunder; 
 (o) the Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this CVR
Agreement; and 
 (p) in no event shall the Trustee be responsible or liable for any failure or delay in the performance of its
obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural
catastrophes or acts of God, and interruptions, loss or malfunctions of utilities or communications services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to
resume performance as soon as practicable under the circumstances. 
 SECTION 4.3 Not Responsible for Recitals or Issuance of
Securities. The Trustee shall not be accountable for the Company’s use of the Securities by any Person other than the Trustee. The recitals contained herein and in the Securities, except the Trustee’s certificates of authentication,
shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the Securities. 

SECTION 4.4 May Hold Securities. The Trustee, any Paying Agent, Security Registrar or any other agent of the Company, in its
individual or any other capacity, may become 

  
 28 

 
the owner or pledgee of Securities, and, subject to SECTIONS 4.7 and 4.12, may otherwise deal with the Company with the same rights it would have if it were not Trustee, Paying Agent, Security
Registrar or such other agent. 
 SECTION 4.5 Money Held in Trust. Money held by the Trustee in trust hereunder need not
be segregated from other funds except to the extent required by Law. The Trustee shall be under no liability for interest on any money received by it hereunder, except as otherwise agreed by the Trustee in writing with the Company. 

SECTION 4.6 Compensation and Reimbursement. The Company agrees: 

(a) to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such amount as the
Company and the Trustee shall agree from time to time (which compensation shall not be limited by any provision of Law in regard to the compensation of a trustee of an express trust); 

(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable expenses, disbursements
and advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such expense,
disbursement or advance as may be attributable to the Trustee’s gross negligence, bad faith or willful misconduct; and 

(c) to indemnify the Trustee and any predecessor Trustee and each of their respective agents, officers, directors and employees (each an
“indemnitee”) for, and to hold them harmless against, any loss, liability or expense (including attorneys fees and expenses) incurred without negligence or bad faith on its part, arising out of or in connection with the acceptance
or administration of this trust and the performance of their duties hereunder, including the reasonable costs and expenses of defending themselves against any claim or liability in connection with the exercise or performance of any of their powers
or duties hereunder. The Company’s payment obligations pursuant to this SECTION 4.6 shall survive the termination of this CVR Agreement. When the Trustee incurs expenses after the occurrence of a Breach specified in SECTION 8.1(c) or 8.1(d)
with respect to the Company, the expenses are intended to constitute expenses of administration under bankruptcy Laws. 
 In
order to secure the payment obligations of the Company in this SECTION 4.6, the Trustee shall have a lien prior to the Securities on all money or property held or collected by the Trustee except such money or property held in trust to make CVR
Payments. 
 SECTION 4.7 Disqualification; Conflicting Interests. 

(a) If applicable, to the extent that the Trustee or the Company determines that the Trustee has a conflicting interest within the meaning
of the Trust Indenture Act, the Trustee shall 

  
 29 

 
immediately notify the Company of such conflict and, within ninety (90) days after ascertaining that it has such conflicting interest, either eliminate such conflicting interest or resign to
the extent and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this CVR Agreement. The Company shall take prompt steps to have a successor appointed in the manner provided in this CVR Agreement. 

(b) In the event the Trustee shall fail to comply with the foregoing subsection 4.7(a), the Trustee shall, within ten (10) days of
the expiration of such ninety (90) day period, transmit a notice of such failure to the Holders in the manner and to the extent provided in the Trust Indenture Act and this CVR Agreement. 

(c) In the event the Trustee shall fail to comply with the foregoing subsection 4.7(a) after written request therefor by the Company or
any Holder, any Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of such Trustee and the
appointment of a successor Trustee. 
 SECTION 4.8 Corporate Trustee Required; Eligibility. There shall at all times be a
Trustee hereunder which satisfies the applicable requirements of Sections 310(a)(1) and (5) of the Trust Indenture Act and has a combined capital and surplus of at least one hundred fifty million dollars ($150,000,000). If such corporation
publishes reports of condition at least annually, pursuant to Law or to the requirements of a supervising or examining authority, then for the purposes of this SECTION 4.8, the combined capital and surplus of such corporation shall be deemed to be
its combined capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this SECTION 4.8, it shall resign immediately in the manner
and with the effect hereinafter specified in this ARTICLE 4. 
 SECTION 4.9 Resignation and Removal; Appointment of
Successor. 
 (a) No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this ARTICLE
4 shall become effective until the acceptance of appointment by the successor Trustee under SECTION 4.10. 
 (b) The Trustee, or
any trustee or trustees hereafter appointed, may resign at any time by giving written notice thereof to the Company. If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within thirty (30) days
after the giving of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor Trustee. 
 (c) The Trustee may be removed at any time by a demand in writing by the Holders of at least a majority of the Outstanding CVRs delivered to the Trustee and to the Company. 

  
 30 

 (d) If at any time: 

(i) the Trustee shall fail to comply with SECTION 4.7 after written request therefor by the Company or by any Holder who
has been a bona fide Holder of a Security for at least six (6) months; or 
 (ii) the Trustee shall cease to
be eligible under SECTION 4.8 and shall fail to resign after written request therefor by the Company or by any such Holder; or 
 (iii) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge
or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, 
 then, in any case,
(A) the Company, by a Board Resolution or action of its Chief Executive Officer, may remove the Trustee, or (B) the Holder of any Security who has been a bona fide Holder of a Security for at least six (6) months may, on behalf of
himself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 
 (e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall occur in the office of Trustee for any cause, the Company, by a Board Resolution and/or action of its Chief
Executive Officer, shall promptly appoint a successor Trustee. If, within one (1) year after any removal by the Holders of at least a majority of the Outstanding CVRs, a successor Trustee shall be appointed by act of the Holders of at least a
majority of the Outstanding CVRs delivered to the Company and the retiring Trustee the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with SECTION 4.10, become the successor Trustee and
supersede the successor Trustee appointed by the Company. If no successor Trustee shall have been so appointed by the Company or the Holders of the Securities and accepted appointment within sixty (60) days after the retiring Trustee tenders
its resignation or is removed, the retiring Trustee may (at the expense of the obligor), or, the Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated,
petition any court of competent jurisdiction for the appointment of a successor Trustee. If any Trustee is removed with or without cause, all fees and expenses (including the reasonable fees and expenses of counsel) of such Trustee incurred in the
administration of the trust or in performing its duties hereunder shall be paid to such Trustee. 
 (f) The Company shall give
notice of each resignation and each removal of the Trustee and each appointment of a successor Trustee by mailing written notice of such event by first-class mail, postage prepaid, to the Holders of Securities as their names and addresses appear in
the Security Register. Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office. If the Company fails to send such notice within ten (10) days after acceptance of appointment by a successor
Trustee, it shall not be a breach hereunder but the successor Trustee shall cause the notice to be mailed at the expense of the Company. 

  
 31 

 SECTION 4.10 Acceptance of Appointment of Successor. 

(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to the Company and to the retiring Trustee an
instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers,
trusts and duties of the retiring Trustee; but, upon request of the Company or the successor Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee all the rights,
powers and trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, the Company shall execute
any and all instruments for more fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and trusts. Notwithstanding the replacement of the Trustee pursuant to this SECTION 4.10, the Company’s obligations
under SECTION 4.6 shall continue and inure to the benefit of the retiring Trustee. 
 (b) No successor Trustee shall accept its
appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this ARTICLE 4. 

SECTION 4.11 Merger, Conversion, Consolidation or Succession to Business. Any corporation into which the Trustee may be merged or
converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all of the corporate trust
business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder, provided such corporation shall be otherwise qualified and eligible under this ARTICLE 4, without the execution or filing of any paper or any
further act on the part of any of the Parties hereto. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating Trustee
may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities; and such certificate shall have the full force which it is anywhere in the
Securities or in this CVR Agreement provided that the certificate of the Trustee shall have; provided that the right to adopt the certificate of authentication of any predecessor Trustee shall apply only to its successor or successors by
merger, conversion or consolidation. 
 SECTION 4.12 Preferential Collection of Claims Against Company. If and when the
Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of the Company (or any other obligor upon the Securities), excluding any creditor relationship set forth in Section 311(b) of the Trust Indenture Act, if
applicable, the Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor). 

  
 32 

 ARTICLE 5 
 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY 
 SECTION 5.1
Company to Furnish Trustee with Names and Addresses of Holders. The Company shall furnish or cause to be furnished to the Trustee (a) promptly after the issuance of the Securities, and semi-annually thereafter, a list, in such form as
the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and (b) at such times as the Trustee may request in writing, within thirty (30) days after receipt by the Company of any such request, a
list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a date not more than fifteen (15) days prior to the time such list is furnished; provided, however, that if and so long as
the Trustee shall be the Security Registrar, no such list need be furnished. 
 SECTION 5.2 Preservation of Information;
Communications to Holders. 
 (a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names
and addresses of the Holders contained in the most recent list furnished to the Trustee as provided in SECTION 5.1 and the names and addresses of Holders received by the Trustee in its capacity as Security Registrar. The Trustee may destroy any list
furnished to it as provided in SECTION 5.1 upon receipt of a new list so furnished. 
 (b) The rights of the Holders to
communicate with other Holders with respect to their rights under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section 312(b)(2) of the Trust Indenture Act, if applicable. 

(c) Every Holder of Securities, by receiving and holding the same, agrees with the Company and the Trustee that neither the Company nor
the Trustee shall be deemed to be in violation of Law or held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders made pursuant to the Trust Indenture Act (if applicable) regardless of the
source from which such information was derived. 
 SECTION 5.3 Reports by Trustee. 

(a) Within sixty (60) days after December 31 of each year commencing with the December 31 following the date of this CVR
Agreement, the Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to Section 313(a) of the Trust Indenture Act to the extent and in the manner provided
pursuant thereto. The Trustee shall also comply with Section 313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall also transmit by mail all reports as required by Section 313(c) of the Trust Indenture Act, if applicable.

 (b) A copy of each such report shall, at the time of such transmission to the Holders, be filed by the Trustee with each
stock exchange, if any, upon which the Securities are listed, with the Commission and also with the Company. The Company shall promptly notify the Trustee when the Securities are listed or delisted on any stock exchange. 

  
 33 

 SECTION 5.4 Reports by Company. The Company shall: (a) file with the Trustee,
(i) within fifteen (15) days after the Company files or furnishes the same with the Commission, copies of the annual reports filed on Form 10-K and the quarterly reports filed on Form 10-Q, and of the information, documents and other
reports (or copies of such portions of any of the foregoing as the Commission may from time to time by rules and regulations prescribe) which the Company is required to file with or furnish to the Commission, pursuant to Section 13 or
Section 15(d) of the Exchange Act (such annual and quarterly reports and required information, documents and other reports, together the “Exchange Act Documents”), (ii) if the Company does not file such annual and
quarterly reports with the Commission, within forty-five (45) days after each fiscal quarter (other than the last quarter of each fiscal year), quarterly financial information and, within ninety (90) days after each calendar year, annual
financial information, in each case calculated in accordance with Accounting Standards, (iii) copies of any quarterly financial information or earnings reports made public by the Company or made available on the Company’s website, within
fifteen (15) days after such information or reports are furnished or otherwise made public or available, (iv) within fifteen (15) days after the end of each calendar month during a calendar year other than the last calendar month, and
within thirty (30) days after the end of the last calendar month of a calendar year, a Product Sales Statement, and (v) within four (4) Business Days after the occurrence of the Approval Milestone, a notice setting forth the
occurrence of the Milestone, the amount of the payment payable in connection with such Milestone and the applicable Payment Date of such Milestone; (b) file with the Trustee such additional information, documents and reports with respect to
compliance by the Company with the conditions and covenants of this CVR Agreement as may be required from time to time by the Trustee or the rules and regulations of the Commission; and (c) make available on the Company’s website as of an
even date with the filing of such materials with the Trustee, the information, documents and reports required to be filed by the Company pursuant to subsections (a) or (b) of this SECTION 5.4. 

SECTION 5.5 Compliance Certificate. The Company shall comply with Section 314(a)(4) of the Trust Indenture Act, to the extent
applicable, by delivering to the Trustee an Officers’ Certificate within one hundred and twenty (120) days after the end of each fiscal year of the Company ending after the date hereof, to be executed by the principal executive officer,
principal financial officer or principal accounting officer of the Company and stating whether or not, to the best knowledge of the signer(s) thereof, the Company is in breach in the performance and observance of any of the terms, provisions or
conditions of this CVR Agreement (without regard to any period of grace or requirement of notice provided hereunder). 

  
 34 

 ARTICLE 6 
 AMENDMENTS 
 SECTION 6.1 Amendments without Consent of Holders. Without the
consent of any Holders, the Company and the Trustee, at any time and from time to time, may enter into one or more amendments hereto or to the Securities, for any of the following purposes: 

(a) to convey, transfer, assign, mortgage or pledge to the Trustee as security for the Securities any property or assets; 

(b) to evidence the succession of another Person to the Company, and the assumption by any such successor of the covenants of the Company
herein and in the Securities; 
 (c) to add to the covenants of the Company such further covenants, restrictions, conditions or
provisions as the Board of Directors and/or the Chief Executive Officer of the Company and the Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence and continuance, of a breach
in any such additional covenants, restrictions, conditions or provisions a Breach permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; provided, that in respect of any such additional
covenant, restriction, condition or provision, such amendment may provide for a particular period of grace after breach (which period may be shorter or longer than that allowed in the case of other breaches) or may provide for an immediate
enforcement upon such a Breach or may limit the remedies available to the Trustee upon such a Breach or may limit the right of the Acting Holders to waive such a Breach; 
 (d) to cure any ambiguity, or to correct or supplement any provision herein or in the Securities which may be defective or inconsistent with any other provision herein; provided that such amendment
shall not adversely affect the interests of the Holders; 
 (e) to make any other provisions with respect to matters or
questions arising under this CVR Agreement; provided that such provisions shall not adversely affect the interests of the Holders; 
 (f) to make any amendments or changes necessary to comply or maintain compliance with the Trust Indenture Act, if applicable; or 
 (g) make any change that does not adversely affect the interests of the Holders. 

Promptly following any amendment of this CVR Agreement or the Securities in accordance with this SECTION 6.1, the Company shall notify
the Holders of the Securities of such amendment; provided, that any failure so to notify the Holders shall not affect the validity of such amendment. 
 SECTION 6.2 Amendments with Consent of Holders. With the consent of the Holders of at least a majority of the Outstanding CVRs, by Act of said Holders delivered to the Company and the Trustee
(including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, the Securities), the Company (when authorized by a Board Resolution and/or its Chief Executive Officer) and the Trustee may
enter into one or more amendments hereto or to the Securities for the purpose of adding any provisions to or changing in any manner 

  
 35 

 
or eliminating any of the provisions of this CVR Agreement or to the Securities or of modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities;
provided, however, that no such amendment shall, without the consent of the Holder of each Outstanding Security affected thereby: 
 (a) modify in a manner adverse to the Holders (i) any provision contained herein with respect to the termination of this CVR Agreement or the Securities, (ii) the time for payment and amount of
any Product Sales Milestone Payment or the Approval Milestone Payment, or otherwise extend the time for payment of the Securities or reduce the amounts payable in respect of the Securities or modify any other payment term or Payment Date;

 (b) reduce the number of CVRs; or 
 (c) modify any of the provisions of this SECTION 6.2, except to increase the percentage of Holders from whom consent is required or to provide that certain other provisions of this CVR Agreement cannot be
modified or waived without the consent of the Holder of each Security affected thereby. 
 SECTION 6.3 Execution of
Amendments. In executing any amendment permitted by this ARTICLE 6, the Trustee (subject to SECTION 4.1) shall be fully protected in relying upon (i) an Opinion of Counsel and Officer’s Certificate stating that the execution of such
amendment is authorized or permitted by this CVR Agreement and (ii) if such amendment is executed pursuant to SECTION 6.2, evidence of the consent of the Holders required to consent thereto. The Trustee shall execute any amendment authorized
pursuant to this ARTICLE 6 if the amendment does not adversely affect the Trustee’s own rights, duties or immunities under this CVR Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment. 

SECTION 6.4 Effect of Amendments; Notice to Holders. 
 (a) Upon the execution of any amendment under this ARTICLE 6, this CVR Agreement and the Securities shall be modified in accordance therewith, and such amendment shall form a part of this CVR Agreement
and the Securities for all purposes; and every Holder of Securities theretofore or thereafter authenticated, as applicable, and delivered hereunder shall be bound thereby. 
 (b) Promptly after the execution by the Company and the Trustee of any amendment pursuant to the provisions of this ARTICLE 6, the Company shall mail a notice thereof by first-class mail to the Holders of
Securities at their addresses as they shall appear on the Security Register, setting forth in general terms the substance of such amendment. Any failure of the Company to mail such notice, or any defect therein, shall not, however, in any way impair
or affect the validity of any such amendment. 
 SECTION 6.5 Conformity with Trust Indenture Act. Every amendment
executed pursuant to this ARTICLE 6 shall conform to the applicable requirements of the Trust Indenture Act, if any. 

  
 36 

 SECTION 6.6 Reference in Securities to Amendments. If an amendment changes the terms
of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee. Securities authenticated and delivered after the execution of any amendment pursuant to this ARTICLE 6 may, and shall if required by the Trustee, bear a
notation in form approved by the Trustee as to any matter provided for in such amendment. If the Company shall so determine, new Securities so modified as to conform, in the opinion of the Trustee on the one hand and the Board of Directors and/or
the Chief Executive Officer of the Company on the other hand, to any such amendment may be prepared and executed by the Company, as applicable, and authenticated, as applicable, and delivered by the Trustee in exchange for Outstanding Securities.
Failure to make the appropriate notation or to issue a new Security shall not affect the validity of such amendment. 
 ARTICLE 7

 COVENANTS 
 SECTION 7.1 Payment of Amounts, if any, to Holders. The Company shall duly and punctually pay the amounts, if any, on the Securities in accordance with the terms of the Securities and this CVR
Agreement. Such amounts shall be considered paid on the applicable Payment Date if on such date the Trustee or the Paying Agent holds in accordance with this CVR Agreement money sufficient to pay all such amounts then due. Notwithstanding any other
provision of this CVR Agreement, the Company or any of its Affiliates (including the Surviving Corporation, as applicable), the Trustee or the Paying Agent, shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any
amounts payable or otherwise deliverable pursuant to this CVR Agreement to any Holder such amounts as are required to be deducted and withheld therefrom under the Code or the Treasury Regulations thereunder or any other Tax Law. If Trustee or the
Paying Agent intends to withhold any amounts from amounts payable under this CVR Agreement, then Trustee or the Paying Agent shall provide thirty (30) days advance notice of such intended withholding to the payee explaining the basis therefor
in order to give the payee an opportunity to provide any information or documentation that may be necessary in order to prevent such withholding. 
 SECTION 7.2 Maintenance of Office or Agency. 
 (a) As long as any of the
Securities remain Outstanding, the Company shall maintain in the city of New York an office or agency (i) where Securities may be presented or surrendered for payment, (ii) where Securities may be surrendered for registration of transfer
or exchange and (iii) where notices and demands to or upon the Company in respect of the Securities and this CVR Agreement may be served. The Corporate Trust Office shall be such office or agency of

  
 37 

 
the Company, unless the Company shall designate and maintain some other office or agency for one or more of such purposes. The Company or any of its Subsidiaries may act as Paying Agent,
registrar or transfer agent; provided that such Person shall take appropriate actions to avoid the commingling of funds. The Company shall give prompt written notice to the Trustee of any change in the location of any such office or agency.
If at any time the Company shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the
Trustee as its agent to receive all such presentations, surrenders, notices and demands. 
 (b) The Company may from time to
time designate one or more other offices or agencies (in or outside of the city of New York) where the Securities may be presented or surrendered for any or all such purposes, and may from time to time rescind such designation; provided,
however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the city of New York for such purposes. The Company shall give prompt written notice to the Trustee
of any such designation or rescission and any change in the location of any such office or agency. 
 SECTION 7.3 Money for
Security Payments to Be Held in Trust. 
 (a) If the Company or any of its Subsidiaries shall at any time act as the Paying
Agent, it shall, on or before the Payment Date, as the case may be, segregate and hold in trust for the benefit of the Holders all sums held by such Paying Agent for payment on the Securities until such sums shall be paid to the Holders as herein
provided, and shall promptly notify the Trustee of any failure of the Company to make payment on the Securities. 
 (b) Whenever
the Company shall have one or more Paying Agents for the Securities, it shall, on or before a Payment Date deposit with a Paying Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due; such sum to be held in trust for
the benefit of the Persons entitled to such amount, and (unless such Paying Agent is the Trustee) the Company shall promptly notify the Trustee of such action or any failure so to act. 

(c) The Company shall cause each Paying Agent other than the Trustee to execute and deliver to the Trustee an instrument in which such
Paying Agent shall agree with the Trustee, subject to the provisions of this SECTION 7.3, that (i) such Paying Agent shall hold all sums held by it for the payment of any amount payable on Securities in trust for the benefit of the Persons
entitled thereto until such sums shall be paid to such Persons or otherwise disposed of as herein provided and shall notify the Trustee of the sums so held and (ii) that it shall give the Trustee notice of any failure by the Company (or by any
other obligor on the Securities) to make any payment on the Securities when the same shall be due and payable. 
 (d) Any money
deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment on any Security and remaining unclaimed for one (1) year after the Payment Date shall be paid to the Company on Company Request, or (if then
held by the Company) shall be discharged from such trust; and the Holder of such Security shall thereafter, as an unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with
respect to such trust money shall thereupon cease. 

  
 38 

 SECTION 7.4 Certain Purchases and Sales. The Company or any of its Subsidiaries or
Affiliates may acquire in open market transactions, private transactions or otherwise, the Securities, provided that prior to any acquisition of any Securities, the Company must publicly disclose the amount of Securities which it has been
authorized to acquire and the Company must report in each of its annual and quarterly reports the amount of Securities it has been authorized to acquire as well as the amount of Securities it has acquired as of the end of the quarterly or annual
period reported in such quarterly or annual report. 
 SECTION 7.5 Books and Records. The Company shall keep, and shall
cause its Subsidiaries to keep, true, complete and accurate records in sufficient detail to enable the amounts payable under this CVR Agreement to be determined by the Holders and their consultants or professional advisors, for a period of three
(3) years following the Termination Date. 
 SECTION 7.6 Audits. 

(a) Upon the written request of the Acting Holders (but no more than once during any calendar year), and upon reasonable notice, the
Company shall provide an independent certified public accounting firm of nationally recognized standing jointly agreed upon by the Acting Holders and the Company (failing agreement on which each shall designate an independent public accounting firm
of its own selection, which firms shall in turn appoint an independent public accounting firm for such purpose) (the “Independent Accountant”) with access during normal business hours to such of the records of the Company as may be
reasonably necessary to verify the accuracy of the statements set forth in the Product Sales Statements and the figures underlying the calculations set forth therein for any period within the preceding three (3) years that has not previously
been audited in accordance with this SECTION 7.6. The fees charged by such accounting firm shall be paid by the Company. The Independent Accountant shall disclose to the Acting Holders any matters directly related to their findings and shall
disclose whether it has determined that any statements set forth in the Product Sales Statements are incorrect. The Independent Accountant shall provide the Company with a copy of all disclosures made to the Acting Holders. This covenant shall
survive the termination of this CVR Agreement for a period of one (1) year. The initiation of a review by the Acting Holders as contemplated by this SECTION 7.6 shall not relieve the Company of its obligation to pay any Product Sales Milestone
Payment relating to any Product Sales Milestone for which notice of achievement has been given in a Product Sales Statement, it being understood that the Company shall also be obligated to pay the full amount of the CVR Shortfall, if any, determined
in accordance with SECTION 7.6(b). 
 (b) If the Independent Accountant concludes that any Product Sales Milestone Payment
should have been paid but was not paid when due, the Company shall pay each Holder of a CVR the amount of such Product Sales Milestone Payment (to the extent not paid on a 

  
 39 

 
subsequent date), as applicable, plus interest on such Product Sales Milestone Payment, as applicable, at the Shortfall Interest Rate from the date the Product Sales Milestone Payment Date should
have occurred (if the Company had given notice of achievement of such Product Sales Milestone pursuant to the terms of this CVR Agreement), as applicable, to the date of actual payment (such amount including interest being the “CVR
Shortfall”). The Company shall pay the CVR Shortfall to the CVR Holders of record as of a date that is three (3) Business Days prior to a Payment Date selected by the Company, which Payment Date must be within sixty (60) days of
the date the Acting Holders deliver to the Company the Independent Accountant’s written report (the “Shortfall Report”). The decision of such Independent Accountant shall be final, conclusive and binding on the Company and the
Holders, shall be non­appealable and shall not be subject to further review. 
 (c) Each Person seeking to receive
information from the Company in connection with a review or audit shall enter into, and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with the Company obligating such party to retain
all such financial information disclosed to such party in confidence pursuant to such confidentiality agreement and not use such information for any purpose other than the completion of such review or audit. 

(d) The Company shall not, and shall cause its Affiliates not to, enter into any license or distribution agreement with any third party
(other than the Company or its Affiliates) with respect to a Product unless such agreement contains provisions that would allow any Independent Accountant appointed pursuant to this SECTION 7.6 such access to the records of the other party to such
license or distribution agreement as may be reasonably necessary to perform its duties pursuant to this SECTION 7.6; provided that the Company and its Affiliates shall not be required to amend any Existing Licenses. The Parties agree that, if
the Company or its Affiliates have exercised audit rights under any license or distribution agreement prior to the Acting Holders’ request for an audit under this SECTION 7.6 and under such license or distribution agreement the Company and its
Affiliates cannot request another audit, the results of the Company’s prior audit of such licensee or distributor shall be used for purposes of the audit requested by the Acting Holders under this SECTION 7.6 and that the Company shall not have
any further obligation to provide access to an Independent Accountant with respect to such licensee until such time as the Company may again exercise its rights of audit under the license agreement with such licensee. 

SECTION 7.7 Listing of CVRs. The Company hereby covenants and agrees it shall use its commercially reasonable efforts to maintain
a listing for trading on the Nasdaq Global Select Market, Nasdaq Global Market, or other national securities exchange for so long as any CVRs remain Outstanding. 
 SECTION 7.8 Product Transfer. Subject to ARTICLE 9, so long as the Securities remain Outstanding, the Company and its Affiliates may not, directly or indirectly, by a sale or swap of assets,
merger, reorganization, joint venture, lease, license, or any other transaction or arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to a Product to a third party (other than the Company or its Affiliates)
(such transaction, a “Product  

  
 40 

 
Disposition Transaction”), unless (a) the Company (or its successor including, if applicable, a Person to whom all of the Company’s and its Subsidiaries’ interests in
the relevant Product are transferred) shall agree to remain subject to the obligations hereunder to make any Product Sales Milestone Payments and the Approval Milestone Payment if and when such a payment is due in accordance with the terms of this
CVR Agreement and (b) at all times after the closing of such Product Disposition Transaction and prior to the Termination Date the gross amounts invoiced for Products by the applicable transferee will be reflected in the Product Sales in
accordance with the terms hereunder (with the transferee substituted for the Company for the purposes of the definition of “Product Sales”) as if such transferee was the Company and the agreement for such Product Disposition Transaction
requires the transferee to comply with the covenants in this SECTION 7.8 and in SECTION 7.6 hereof to the same extent as the Company. For purposes of clarification, this SECTION 7.8 shall not apply to sales of a Product made by the Company
or its Affiliates or ordinary course licensing arrangements between the Company and its Affiliates, on the one hand, and third party licensees, distributors and contract manufacturers, on the other hand, entered into in the ordinary course of
business for purposes of developing, manufacturing, distributing and/or selling such Product and for which the gross amounts invoiced for sales of such Product by the applicable third party licensee, distributor or contract manufacturer shall be
reflected in Product Sales in accordance with the terms of this CVR Agreement. 
 SECTION 7.9 Milestones. 

(a) Subject to SECTIONS 7.9(b), (c) and (d) below, the Company, directly or through its Affiliates, licensees and/or other
contractors, shall use Diligent Efforts to achieve (i) the Approval Milestone and (ii) the Product Sales Milestones through sales of Marketed Products. 
 (b) The Company shall have no obligation to pursue the Approval Milestone if the FDA issues an order under 21 CFR 814.45 denying FDA Approval of the AUGMENT PMA. Further, and for the avoidance of
doubt, in the event the FDA requires any additional clinical efficacy trial(s), post-marketing study(ies) (other than customary post-approval patient registries) or otherwise requests additional information that cannot be derived from
BioMimetic’s completed clinical studies, the Company, its Affiliates and/or licensees will not be required to undertake any of the foregoing, and any election by the Company, its Affiliates and/or licensees not to do so will not be deemed a
failure to exercise Diligent Efforts under this Agreement. For purposes of the foregoing sentence, additional safety trials such as pharmacokinetic studies and similar studies with non-efficacy based endpoints that are reasonably capable of being
performed in less than eighteen (18) months will not be considered clinical efficacy trials. 
 (c) The Company’s
obligation to use Diligent Efforts to achieve the Product Sales Milestones with respect to AUGMENT Bone Graft do not require the Company, its Affiliates and/or licensees to seek or obtain approval to market and sell AUGMENT Bone Graft (i) in
any jurisdiction other than the United States, nor (ii) for any indication other than the indications approved by the FDA in the first FDA Approval of AUGMENT Bone Graft (assuming any such approval is obtained). 

(d) Except as expressly set forth in SECTION 7.9(a) above with respect to AUGMENT Bone Graft, the Company shall have no obligation
(i) to seek new or expanded 

  
 41 

 
regulatory approvals for any Product, (ii) to develop or introduce new Products or (iii) to commercialize any Product in any jurisdiction where such Product was not legally
commercialized as of the date of this CVR Agreement. No failure of the Company, its Affiliates and/or licensees to do any of the foregoing will be deemed a failure to use Diligent Efforts hereunder. Further, and without in any way inferring that the
application of Diligent Efforts would otherwise bar the Company, its Affiliates and/or licensees from electing in good faith to discontinue the marketing and sale of a Product, it is understood and agreed that if the Company, or any of its
Affiliates or licensees, elects for any reason to suspend or discontinue the marketing and sale of AUGMATRIX Bone Graft in any jurisdiction (or in all jurisdictions), such decision shall not be deemed a failure by the Company to use Diligent Efforts
hereunder. 
 SECTION 7.10 Notice of Breach. The Company shall file with the Trustee written notice of the occurrence of
any Breach or other breach under this CVR Agreement within five (5) Business Days of its becoming aware of any such Breach or other breach. 
 SECTION 7.11 Non-Use of Name. Neither the Trustee nor the Holders shall use the name, trademark, trade name or logo of the Company, its Affiliates, or their respective employees in any publicity or
news release relating to this CVR Agreement or its subject matter, without the prior express written permission of the Company, other than (in the case of the name of the Company, its Affiliates, or their respective employees) with respect to a
dispute pursuant to this CVR Agreement between any of the Holders, the Trustee, the Company or its Affiliates. 
 ARTICLE 8

 REMEDIES OF THE TRUSTEE AND HOLDERS IN THE EVENT OF BREACH 

SECTION 8.1 Breach Defined; Waiver of Breach. “Breach” with respect to the Securities, means each one of the
following events which shall have occurred and be continuing (whatever the reason for such Breach and whether it shall be voluntary or involuntary or be effected by operation of Law or pursuant to any judgment, decree or order of any court or any
order, rule or regulation of any administrative or governmental body): 
 (a) failure to pay all or any part of any CVR Payment
after a period of ten (10) Business Days after such CVR Payment shall become due and payable on a Payment Date or otherwise; or 
 (b) material breach in the performance, or breach in any material respect, of any covenant or warranty of the Company in respect of the Securities (other than a covenant or warranty in respect of the
Securities, a breach in whose performance or other breach is elsewhere in this SECTION 8.1 specifically dealt with), and continuance of such breach for a period of ninety (90) days after there has been given, by registered or certified mail, to
the Company by the Trustee or to the Company and the Trustee by the Acting Holders, a written notice specifying such breach and requiring it to be remedied and stating that such notice is a “Notice of Breach” hereunder; or 

  
 42 

 (c) a court having jurisdiction in the premises shall enter a decree or order for relief in
respect of the Company in an involuntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of
the Company or for any substantial part of its property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of ninety (90) consecutive days; or 

(d) the Company shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in
effect, or consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of
the Company or for any substantial part of its property, or make any general assignment for the benefit of creditors. 
 Except
where authorization and/or appearance of each of the Holders is required by applicable Law, if a Breach described above occurs and is continuing, then either the Trustee by notice in writing to the Company, or the Trustee upon the written request of
the Acting Holders by notice in writing to the Company and to the Trustee, may, as provided in SECTION 8.2, bring suit to protect the rights of the Holders, including to obtain payment for any amounts then due and payable, which amounts shall bear
interest at the Breach Interest Rate from the date such amounts were due and payable until payment is made to the Trustee. 

The foregoing provisions, however, are subject to the condition that if, at any time after the Trustee shall have begun such suit, and
before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay all amounts which shall have become due and
payable (with interest upon such overdue amount at the Breach Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee, its agents, attorneys and counsel, and all
other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Breaches under this CVR Agreement shall have been cured, waived or otherwise remedied as provided herein, then and in every such case Holders of at
least a majority of the Outstanding CVRs, by Act of said Holders delivered to the Company and the Trustee, may waive all breaches with respect to the Securities, but no such waiver or rescission and annulment shall extend to or shall affect any
subsequent breach or shall impair any right consequent thereof. 
 SECTION 8.2 Collection by the Trustee; the Trustee May
Prove Payment Obligations. The Company covenants that in the case of any failure to pay all or any part of the Securities when the same shall have become due and payable, whether at a Payment Date or otherwise, then upon demand of the Trustee,
the Company shall pay to the Trustee for the benefit of the Holders of the Securities the whole amount that then shall have become due and payable on all Securities (with interest from the date due and payable to the date of such payment upon the
overdue amount at the Breach Interest Rate); and in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their
respective agents, attorneys and counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of the Trustee’s gross negligence or bad faith. 

  
 43 

 The Trustee may in its discretion proceed to protect and enforce its rights and the rights
of the Holders by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this CVR Agreement or in aid of the
exercise of any power granted herein, or to enforce any other remedy. 
 In case the Company shall fail forthwith to pay such
amounts upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute
any such action or proceedings to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon such Securities and collect in the manner provided by Law out of the property of the Company or
other obligor upon such Securities, wherever situated, the moneys adjudged or decreed to be payable. 
 In any judicial
proceedings relative to the Company or other obligor upon the Securities, irrespective of whether any amount is then due and payable with respect to the Securities, the Trustee is authorized: 

(a) to file and prove a claim or claims for the whole amount owing and unpaid in respect of the Securities, and to file such other papers
or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each predecessor Trustee, and their respective agents, attorneys and counsel, and for
reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of the Trustee’s gross negligence or bad faith) and of the Holders allowed in any judicial
proceedings relative to the Company or other obligor upon the Securities, or to their respective property; 
 (b) unless
prohibited by and only to the extent required by applicable Law, to vote on behalf of the Holders in any election of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or Person
performing similar functions in comparable proceedings; and 
 (c) to collect and receive any moneys or other property payable
or deliverable on any such claims, and to distribute all amounts received with respect to the claims of the Holders and of the Trustee on their behalf; and any trustee, receiver, or liquidator, custodian or other similar official is hereby
authorized by each of the Holders to make payments to the Trustee, and, in the event that the Trustee shall consent to the making of payments directly to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable
compensation to the Trustee, each predecessor Trustee and their respective agents, attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of the
Trustee’s gross negligence or bad faith, and all other amounts due to the Trustee or any predecessor Trustee pursuant to SECTION 4.6. To the extent that such payment of reasonable compensation, expenses, disbursements, advances and other
amounts out 

  
 44 

 
of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, moneys,
securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or safeguard arrangement or otherwise. 

Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of
any Holder any plan of reorganization, safeguard arrangement, adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding
except, as aforesaid, to vote for the election of a trustee in bankruptcy or similar person. 
 All rights of action and of
asserting claims under this CVR Agreement, or under any of the Securities, may be enforced by the Trustee without the possession of any of the Securities or the production thereof and any trial or other proceedings instituted by the Trustee shall be
brought in its own name as trustee of an express trust, and any recovery of judgment, subject to the payment of the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be
for the ratable benefit of the Holders. 
 In any proceedings brought by the Trustee (and also any proceedings involving the
interpretation of any provision of this CVR Agreement to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such Securities parties to any such proceedings
(unless required by applicable Law). 
 SECTION 8.3 Application of Proceeds. Any monies collected by the Trustee pursuant
to this ARTICLE 8 in respect of any Securities shall be applied in the following order at the date or dates fixed by the Trustee upon presentation of the several Securities in respect of which monies have been collected and stamping (or otherwise
noting) thereon the payment in exchange for the presented Securities if only partially paid or upon surrender thereof if fully paid: 
 FIRST: To the payment of costs and expenses in respect of which monies have been collected, including reasonable compensation to the Trustee and each predecessor Trustee and their respective agents
and attorneys and of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of the Trustee’s gross negligence or willful misconduct, and all other amounts due to the Trustee
or any predecessor Trustee pursuant to SECTION 4.6; 
 SECOND: To the payment of the whole amount then
owing and unpaid upon all the Securities, with interest at the Breach Interest Rate on all such amounts, and in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the Securities, then to the payment of such
amounts without preference or priority of any security over any other Security, ratably to the aggregate of such amounts due and payable; and 

  
 45 

 THIRD: To the payment of the remainder, if any, to the Company or any
other Person lawfully entitled thereto. 
 SECTION 8.4 Suits for Enforcement. In case a Breach has occurred, has not been
waived and is continuing, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of
such rights (unless authorization and/or appearance of each of the Holders is required by applicable Law), either at Law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this
CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other legal or equitable right vested in the Trustee by this CVR Agreement or by Law. 

SECTION 8.5 Restoration of Rights on Abandonment of Proceedings. In case the Trustee or any Holder shall have proceeded to enforce
any right under this CVR Agreement and such proceedings shall have been discontinued or abandoned for any reason, or shall have been determined adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee and
the Holders shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company, the Trustee and the Holders shall continue as though no such proceedings had been taken. 

SECTION 8.6 Limitations on Suits by Holders. Subject to the right of the Acting Holders under SECTION 7.6 and the rights of the
Holders under SECTION 8.7, no Holder of any Security shall have any right by virtue or by availing of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or in bankruptcy or otherwise upon or under or with
respect to this CVR Agreement, or for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless: (i) such Holder previously shall have given to the Trustee written notice
of breach and of the continuance thereof, as hereinbefore provided; (ii) the Acting Holders shall have made written request upon the Trustee to institute such action or proceedings in its own name as trustee hereunder; and (iii) such
Holder shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby and the Trustee for fifteen (15) days after its receipt of such notice and
request shall have failed to institute any such action or proceeding and no direction inconsistent with such written request shall have been given to the Trustee pursuant to SECTION 8.9; it being understood and intended, and being expressly
covenanted by the taker and Holder of every Security with every other taker and Holder and the Trustee, that no one or more Holders of Securities shall have any right in any manner whatever by virtue or by availing of any provision of this CVR
Agreement to effect, disturb or prejudice the rights of any other such Holder of Securities, or to obtain or seek to obtain priority over or preference to any other such Holder or to enforce any right under this CVR Agreement, except in the manner
herein provided and for the equal, ratable and common benefit of all Holders of Securities. For the protection and enforcement of the provisions of this SECTION 8.6, each and every Holder and the Trustee shall be entitled to such relief as can be
given either at Law or in equity. 

  
 46 

 SECTION 8.7 Unconditional Right of Holders to Institute Certain Suits.
Notwithstanding any other provision in this CVR Agreement and any provision of any Security, the right of any Holder of any Security to receive payment of the amounts payable in respect of such Security on or after the respective due dates expressed
in such Security, or to institute suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder. 

SECTION 8.8 Powers and Remedies Cumulative; Delay or Omission Not Waiver of Breach. 

(a) Except as provided in SECTION 8.6, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended
to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at Law or in equity or
otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 

(b) No delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Breach occurring and continuing
as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Breach or an acquiescence therein; and, subject to SECTION 8.6, every power and remedy given by this CVR Agreement or by Law to the Trustee or to the
Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. 

SECTION 8.9 Control by Holders. 
 (a) The Holders of at least a majority of the Outstanding CVRs shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising
any power conferred on the Trustee with respect to the Securities by this CVR Agreement; provided that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR Agreement; and provided
further that (subject to the provisions of SECTION 4.1) the Trustee shall have the right to decline to follow any such direction if the Trustee, being advised by counsel, shall determine that the action or proceeding so directed may not
lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee, or a committee of directors or Responsible Officers of the Trustee shall determine that the action or proceedings so directed would involve the
Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances specified in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities not joining in the
giving of said direction. 

  
 47 

 (b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to
take any action deemed proper by the Trustee and which is not inconsistent with such direction or directions by Holders. 

SECTION 8.10 Waiver of Past Breaches. 
 (a) In the case of a breach or a Breach specified in clause (b), (c) or (d) of SECTION 8.1, the Holders of at least a majority of the Outstanding CVRs may waive any such Breach, and its
consequences except a breach in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each Security affected. In the case of any such waiver, the Company, the Trustee and the Holders of
the Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other breach or impair any right consequent thereon. 

(b) Upon any such waiver, such breach shall cease to exist and be deemed to have been cured and not to have occurred, and any Breach
arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall extend to any subsequent or other Breach or other breach of any kind or impair any right consequent
thereon. 
 SECTION 8.11 The Trustee to Give Notice of Breach, But May Withhold in Certain Circumstances. The Trustee
shall transmit to the Holders, as the names and addresses of such Holders appear on the Security Register (as provided under Section 313(c) of the Trust Indenture Act, if applicable), notice by mail of all breaches which have occurred and are
known to the Trustee, such notice to be transmitted within ninety (90) days after the occurrence thereof, unless such breaches shall have been cured before the giving of such notice (the term “breach” for the purposes of this SECTION
8.11 being hereby defined to mean any event or condition which is, or with notice or lapse of time or both would become, a Breach); provided that, except in the case of a failure to pay the amounts payable in respect of any of the Securities,
the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of directors or trustees and/or Responsible Officers of the Trustee in good faith determines that the
withholding of such notice is in the interests of the Holders; and provided, however, that in the case of any breach of the character specified in SECTION 8.1(b) with respect to the Securities, no notice to Holders shall be given until
at least thirty (30) days after the occurrence thereof. 
 SECTION 8.12 Right of Court to Require Filing of Undertaking
to Pay Costs. All Parties to this CVR Agreement agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy
under this CVR Agreement or in any suit against the Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its
discretion assess reasonable costs, including attorneys’ 

  
 48 

 
fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this SECTION 8.12 shall
not apply to any suit instituted by the Trustee, to any suit instituted by any Holder or group of Holders holding in the aggregate more than ten percent (10%) of the Securities Outstanding or to any suit instituted by any Holder for the
enforcement of the payment of any Security on or after the due date expressed in such Security. 
 ARTICLE 9 

CONSOLIDATION, MERGER, SALE OR CONVEYANCE 
 SECTION 9.1 Successor Person Substituted. 
 (a) In case of a consolidation
or merger with a wholly-owned Subsidiary or any other Person, or a transfer or sale to a Person of all or substantially all of the assets or business of Company related to the Products, and following the assumption of this CVR Agreement by such
successor Person, such successor Person shall succeed to and be substituted for the Company with the same effect as if it had been named herein. Such successor Person may cause to be signed, and may issue either in its own name or in the name of the
Company prior to such succession any or all of the Securities issuable hereunder, in the case of Global Securities, which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor
Person instead of the Company and subject to all the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which previously shall have been signed and delivered to the
Trustee for authentication, and any Securities which such successor corporation thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities so issued shall in all respects have the same legal rank and
benefit under this CVR Agreement as the Securities theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such Securities had been issued at the date of the execution hereof. 

(b) In case of any such consolidation or merger or sale described in SECTION 9.1(a), such changes in phraseology and form (but not
in substance) may be made in the Securities thereafter to be issued as may be appropriate. The successor Person to such consolidation or merger may satisfy the obligations of SECTION 5.4(a)(i) and (ii) by providing copies of such successor
entity’s Exchange Act Documents in the case of SECTION 5.4(a)(i) or such successor entity’s financial information in the case of SECTION 5.4(a)(ii). 
 SECTION 9.2 Opinion of Counsel to the Trustee. The Trustee, subject to the provisions of SECTIONS 4.1 and 4.2, shall receive an Officer’s Certificate and Opinion of Counsel, prepared in
accordance with SECTIONS 1.2 and 1.3, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any such assumption, and any such liquidation or dissolution, complies with the applicable provisions of this CVR Agreement,
and if a supplemental agreement is required in connection with such transaction, such supplemental agreement complies with this ARTICLE 9 and that there has been compliance with all conditions precedent herein provided for or relating to such
transaction. 

  
 49 

 SECTION 9.3 Successors. All covenants, provisions and agreements in this CVR
Agreement by or for the benefit of the Company, the Trustee or the Holders shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives, whether so expressed or not. The Company may assign this CVR
Agreement without the prior written consent of the other Parties to this CVR Agreement (i) to one or more of its direct or indirect Subsidiaries or (ii) in connection with the transfer or sale of all or substantially all of the assets or
business of the Company related to the Products, or in the event of the Company’s merger or consolidation , provided, however, that in the event of any such assignment the Company (or its successor) agrees in writing to remain
subject to the obligations and covenants hereunder to make any Product Sales Milestone Payments and the Approval Milestone Payment when such a payment is due in accordance with the terms of this CVR Agreement. 

ARTICLE 10 

SUBORDINATION 

SECTION 10.1 Agreement to Subordinate. The Company agrees, and each Holder by accepting a Security hereunder agrees, that the CVR
Payments, all other obligations under this CVR Agreement and the Securities and any rights or claims relating thereto (collectively, the “Junior Obligations”) are subordinated in right of payment, to the extent and in the manner
provided in this ARTICLE 10 to the prior payment in full in money or money’s worth of all Senior Obligations of the Company (whether outstanding on the date hereof or hereafter created, incurred, assumed or guaranteed), and that the
subordination is for the benefit of the holders of such Senior Obligations. 
 SECTION 10.2 Liquidation; Dissolution;
Bankruptcy. Upon any distribution to creditors of the Company in a liquidation or dissolution of the Company or in a bankruptcy, reorganization, insolvency, receivership or similar proceeding relating to the Company or its property, in an
assignment for the benefit of creditors or any marshaling of the Company’s assets and liabilities: 
 (a) holders of Senior
Obligations will be entitled to receive payment in full in money or money’s worth of all Senior Obligations of the Company (including interest after the commencement of any bankruptcy proceeding at the rate specified in the applicable Senior
Obligation, whether or not permitted under such bankruptcy proceedings) before the Holders will be entitled to receive any payment of any kind with respect to the Junior Obligations (other than securities of the Company or debt of the Company that
is subordinated to the Senior Obligations on terms at least as favorable to holders of Senior Obligations as this ARTICLE 10 (“Permitted Junior Securities”)); and 

(b) until all Senior Obligations of the Company (as provided in clause (a) above) are paid in full in money or money’s worth,
any distribution to which Holders would be entitled but for this ARTICLE 10 (other than Permitted Junior Securities) will be made to holders of Senior Obligations of the Company, as their interests may appear. 

  
 50 

 SECTION 10.3 When Distribution Must be Paid Over. 

(a) In the event that the Trustee or any Holder receives any payment of any Junior Obligations (other than Permitted Junior Securities)
at a time when the Trustee or such Holder has actual knowledge that such payment is prohibited by this ARTICLE 10 , such payment will be held by the Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered,
upon written request, to, the holders of Senior Obligations of the Company as their interests may appear or their representative under the agreement, indenture or other document (if any) pursuant to which such Senior Obligations may have been
issued, as their respective interests may appear, for application to the payment of all such Senior Obligations remaining unpaid to the extent necessary to pay such Senior Obligations in full in accordance with their terms, after giving effect to
any concurrent payment or distribution to or for the holders of Senior Obligations. 
 (b) With respect to the holders of Senior
Obligations, the Trustee undertakes to perform only those obligations on the part of the Trustee as are specifically set forth in this ARTICLE 10, and no implied covenants or obligations with respect to the holders of Senior Obligations will be read
into this CVR Agreement against the Trustee. The Trustee will not be deemed to owe any fiduciary duty to the holders of Senior Obligations, and will not be liable to any such holders if the Trustee pays over or distributes to or on behalf of Holders
or the Company or any other Person money or assets to which any holders of Senior Obligations are then entitled by virtue of this ARTICLE 10, except if such payment is made as a result of the willful misconduct or gross negligence of the Trustee.

 SECTION 10.4 Notice by Company. The Company will promptly notify the Trustee of any facts known to the Company that
would cause a payment of any Junior Obligations to violate this ARTICLE 10, but failure to give such notice will not affect the subordination of the Junior Obligations to the Senior Obligations as provided in this ARTICLE 10. 

SECTION 10.5 Subrogation. After all Senior Obligations are paid in full in money or money’s worth and until the Junior
Obligations are paid in full, Holders will be subrogated to the rights of holders of Senior Obligations to receive distributions applicable to Senior Obligations to the extent that distributions otherwise payable to the Holders have been applied to
the payment of Senior Obligations. The Holders by accepting the Securities acknowledge that to the extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations are subordinated to other obligations of the Company,
such subrogation rights may be impaired. 
 SECTION 10.6 Relative Rights. This ARTICLE 10 defines the relative rights of
Holders and holders of Senior Obligations. Nothing in this CVR Agreement will: 

  
 51 

 (a) impair, as between the Company and Holders, the obligations of the Company under this
CVR Agreement and the Securities; 
 (b) affect the relative rights of Holders and creditors of the Company other than their
rights in relation to holders of Senior Obligations; or 
 (c) prevent the Trustee or any Holder from exercising its available
remedies upon a Default or Event of Default, subject to the rights of holders of Senior Obligations to receive distributions and payments otherwise payable to Holders under this ARTICLE 10. 

If the Company fails because of this ARTICLE 10 to pay any amounts due in respect of the Securities on a due date in violation of
SECTION 3.1(c) or SECTION 3.1(d), the failure is still an Event of Default. 
 SECTION 10.7 Subordination May Not
be Impaired by the Company. No right of any holder of Senior Obligations to enforce the subordination of the Junior Obligations may be impaired by any act or failure to act by the Company or any Holder or by the failure of the Company or any
Holder to comply with this CVR Agreement. 
 SECTION 10.8 Distribution or Notice to the Representative. Whenever a
distribution is to be made or a notice given to holders of Senior Obligations, the distribution may be made and the notice given to their representative in accordance with the terms of the instrument or other agreement governing such Senior
Obligations. Upon any payment or distribution of assets of the Company referred to in this ARTICLE 10, the Trustee and the Holders will be entitled to rely upon any order or decree made by any court of competent jurisdiction or upon any certificate
of such representative or of the liquidating trustee or agent or other Person making any distribution to the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the
Senior Obligations and other obligations of the Company, the amount thereof or payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this ARTICLE 10. 

SECTION 10.9 Rights of the Trustee. Notwithstanding the provisions of this ARTICLE 10 or any other provision of this CVR
Agreement, the Trustee will not be charged with knowledge of the existence of any facts that would prohibit the making of any payment or distribution by the Trustee, and the Trustee may continue to make payments on the Securities, unless the Trustee
has received at its address for notice specified in SECTION 1.5 at least five (5) Business Days prior to the date of such payment written notice of facts that would cause the payment of any Junior Obligations to violate this ARTICLE 10. Only
the Company or a representative of Senior Obligations may give the notice. Nothing in this ARTICLE 10 will impair the claims of, or payments to, the Trustee under or pursuant to SECTION 4.6 hereof. The Trustee in its individual or any other capacity
may hold Senior Obligations with the same rights it would have if it were not the Trustee. 

  
 52 

 SECTION 10.10 Authorization to Effect Subordination. Each Holder, by the
Holder’s acceptance of the Securities, authorizes and directs the Trustee on such Holder’s behalf to take such action as may be necessary or appropriate to effectuate the subordination as provided in this ARTICLE 10, and appoints the
Trustee to act as such Holder’s attorney-in-fact for any and all such purposes. If the Trustee (or any other Person acting on behalf of and at the direction of the Majority Holders) does not file a proper proof of claim or proof of debt in the
form required in any proceeding referred to in SECTION 8.2 hereof at least thirty (30) days before the expiration of the time to file such claim, the representatives of the Senior Obligations are hereby authorized to file an appropriate claim
for and on behalf of the Holders of the Securities. 
 SECTION 10.11 Amendments. The provisions of this ARTICLE 10 are
expressly made for the benefit of the holders from time to time of the Senior Obligations, and may not be amended or modified without the written consent of the representatives of the holders of all Senior Obligations. 

ARTICLE 11 

PURCHASE OF SECURITIES UPON CVR FAILURE EVENT 
 SECTION 11.1 Notice of Trustee. In the event that a Failure Purchase Eligibility Date has occurred and the Company elects to purchase the Securities pursuant to the provisions of SECTION 11.5
hereof (a “Failure Purchase”), it shall furnish to the Trustee, at least thirty (30) days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60) days before the date on which the Company
proposes to consummate the Failure Purchase (any such date, a “Failure Purchase Date”) (but in any event prior to the notice provided pursuant to SECTION 11.2 hereof), an Officer’s Certificate (a “Failure Purchase
Offer”) setting forth (i) the clause of this CVR Agreement pursuant to which the Failure Purchase shall occur, (ii) the Failure Purchase Date, and (iii) the Failure Purchase Price, determined in accordance with SECTION 11.5
hereof. 
 SECTION 11.2 Notice of Failure Purchase. At least thirty (30) days but not more than sixty (60) days
before a Failure Purchase Date, the Company shall mail or cause to be mailed, a notice of Failure Purchase to each Holder at its registered address (the “Failure Purchase Notice”) and shall publicly disclose the election of the
Failure Purchase and the information required to be contained in the Failure Purchase Notice pursuant to this SECTION 11.2. The Failure Purchase Notice shall identify the number of Securities Outstanding and shall state: 

(a) the Failure Purchase Date; 

  
 53 

 (b) the Failure Purchase Price; 

(c) the name and address of the paying agent; 
 (d) that Securities must be surrendered to the Paying Agent to collect the Failure Purchase Price; 
 (e) that, unless the Company fails to make payment of the Failure Purchase Price, all right, title and interest in and to the Securities and any CVR Payment or any other amounts due under this CVR
Agreement, if any, on Securities called for Failure Purchase ceases to accrue on and after the Failure Purchase Date; 
 (f) the
clause of this CVR Agreement pursuant to which the Failure Purchase shall occur; and 
 (g) that no representation is made as to
the correctness or accuracy of the CUSIP and ISIN number, if any, listed in such notice or printed on the Securities. 
 At the
Company’s request, the Trustee shall give the Failure Purchase Notice in the Company’s name and at its expense; provided, however, that the Company shall have delivered to the Trustee at least forty five (45) days (unless a shorter
period shall be agreed to by the Trustee) but not more than sixty (60) days prior to the Failure Purchase Date, an Officer’s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such
notice as provided in the preceding paragraph. 
 SECTION 11.3 Effect of Failure Purchase Notice. Once the Failure
Purchase Notice is mailed in accordance with SECTION 11.2 hereof, the Securities shall become irrevocably due and payable on the Failure Purchase Date at the Failure Purchase Price. A Failure Purchase Notice shall be deemed to be given when mailed,
whether or not the Holder receives the notice. In any event, failure to give a particular Holder his or her Failure Purchase Notice, or any defect in such notice, shall not affect the validity of the proceedings for the Failure Purchase. 

SECTION 11.4 Deposit of Failure Purchase Price. On or one (1) Business Day prior to the Failure Purchase Date, the Company
shall deposit with the Trustee or with the paying agent (if different from the Trustee) money sufficient to pay the Failure Purchase Price of all Securities Outstanding on that date. The Trustee or the paying agent shall promptly return to the
Company any money deposited with the Trustee or the paying agent by the Company in excess of the amounts necessary to pay the Failure Purchase Price of all Securities Outstanding. 

If the Company complies with the provisions of the preceding paragraph, on and after the Failure Purchase Date, all right, title and
interest of a Holder to any CVR Payment, if any, shall cease to accrue on the Securities. If any Security called for Failure Purchase shall not be so paid upon surrender for Failure Purchase because of the failure of the Company to comply with the
preceding paragraph, interest shall be paid on the unpaid Failure Purchase Price from the Failure Purchase Date, until such Failure Purchase Price is paid at the Shortfall Interest Rate. 

  
 54 

 SECTION 11.5 Failure Purchase by the Company. The Company may, for a period of sixty
(60) days after any Failure Purchase Eligibility Date, issue the Failure Purchase Notice in accordance with SECTION 11.2. Upon issuance of the Failure Purchase Notice and in compliance with the other provisions of this ARTICLE 10, the Company
shall, on the Failure Purchase Date specified in such Failure Purchase Notice, purchase and cancel all (but not less than all) of the outstanding Securities at a cash price equal to 115% of the volume weighted average price paid per Security for all
Securities traded over the forty-five (45) trading days prior to the fifth (5th) trading day prior to the date of the Failure Purchase Notice (the “Failure Purchase Price”). If the Company has not issued the Failure
Purchase Notice within such sixty (60) day period after the occurrence of a Failure Purchase Eligibility Date, it shall not be entitled to issue a Failure Purchase Notice and purchase and cancel the Securities until the next instance in which a
Failure Purchase Eligibility Date occurs. 

  
 55 

 IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed,
all as of the day and year first above written. 
  

			
	 Wright Medical Group, Inc.

		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	
	
	 AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC,
 as the Trustee

		
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

  
 56 

 ANNEX A 
 [For Global Securities only: THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE CONTINGENT VALUE RIGHTS AGREEMENT (THE “CVR AGREEMENT”) HEREINAFTER REFERRED TO AND IS
REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY OR A SUCCESSOR DEPOSITARY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF. THIS SECURITY IS NOT EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE
DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT, AND NO TRANSFER OF THIS SECURITY (OTHER THAN A TRANSFER OF THIS SECURITY AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE
DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE CVR AGREEMENT. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DIRECT REGISTRATION FORM,
THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR
DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”) TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF
TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER
ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

 WRIGHT MEDICAL GROUP, INC. 
 No.                              Certificate for
                             Contingent Value Rights
                             
 This certifies that                     , or registered assigns (the “Holder”), is the
registered holder of the number of Contingent Value Rights (“CVRs” or “Securities”) set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in the CVR Agreement referred to on
the reverse hereof, to payments from Wright Medical Group, Inc., a Delaware corporation (the “Company”), in the amounts and in the forms determined pursuant to the provisions set forth on the reverse hereof and as more fully
described in the CVR Agreement referred to on the reverse hereof. Such payments shall be made on a Payment Date, as defined in the CVR Agreement referred to on the reverse hereof. 

  
 A-1

 Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered
Holder (as defined in the CVR Agreement) of this CVR Certificate. Such payment shall be made in the Borough of Manhattan, The City of New York, or at any other office or agency maintained by the Company for such purpose, in such coin or currency of
the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by wire transfer or check payable in such money. American Stock
Transfer & Trust Company, LLC has been initially appointed as Paying Agent at its office or agency in The City of New York. 
 Reference is hereby made to the further provisions of this [Global Security] [CVR Certificate] set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if
set forth at this place. 
 Unless the certificate of authentication hereon has been duly executed by the Trustee referred to on
the reverse hereof by manual signature, this [Global Security] [CVR Certificate] shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose. 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	 [—]
	 	
	 By:
	 	  

	 Name:
	 	
	 Title:
	 	

 [Form of Reverse of Global Security or CVR Certificate] 

1. This [Global Security] [CVR Certificate] is issued under and in accordance with the Contingent Value Rights Agreement, dated as of
                 (the “CVR Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, a New York limited liability
trust company, as trustee (the “Trustee,” which term includes any successor Trustee under the CVR Agreement), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder
of this [Global Security] [CVR Certificate] consents by acceptance hereof. The CVR Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective
rights, limitations of rights, duties, obligations and immunities thereunder of the Company, the Trustee and the Holders of the CVRs. All capitalized terms used in this [Global Security] [CVR Certificate] without definition shall have the respective
meanings ascribed to them in the CVR Agreement. Copies of the CVR Agreement can be obtained by contacting the Trustee. 
 2. In
the event of any conflict between this [Global Security] [CVR Certificate] and the CVR Agreement, the CVR Agreement shall govern and prevail. 
 3. Subject to the terms and conditions of the CVR Agreement, on any Product Sales Milestone Payment Date, the Company shall pay to the Trustee, for the benefit of the Holder hereof as of the applicable
record date, for each CVR represented hereby, the Product Sales Milestone Payment with respect to such Product Sales Milestone Payment Date. 
 4. Subject to the terms and conditions of the CVR Agreement, on the Approval Milestone Payment Date, the Company shall pay to the Trustee, for the benefit of the Holder hereof as of the applicable record
date, for each CVR represented hereby, the Approval Milestone Payment. 
 5. Each CVR Payment, if any, and interest thereon, if
any, shall be payable by the Company in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by its check
or wire transfer payable in such money. American Stock Transfer & Trust Company, LLC has been initially appointed as Paying Agent at its office or agency in The City of New York. 

6. If a Breach occurs and is continuing, either the Trustee may or the Acting Holders, by notice to the Company and to the Trustee shall
bring suit in accordance with the terms and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain payment of all amounts then due and payable, with interest at the Breach Interest Rate from the date of the Breach
through the date payment is made or duly provided for. 
 7. No reference herein to the CVR Agreement and no provision of this
[Global Security] [CVR Certificate] or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any amounts determined pursuant to the terms hereof and of the CVR Agreement at the times,
place and amount, and in the manner, herein prescribed. 

 8. As provided in the CVR Agreement and subject to certain limitations
therein set forth, the transfer of the CVRs represented by this [Global Security] [CVR Certificate] is registrable on the Security Register, upon surrender of this [Global Security] [CVR Certificate] for registration of transfer at the office or
agency of the Company maintained for such purpose in The City of New York, accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new [Global Securities] [CVR Certificates], for the same amount of CVRs, shall be issued to the designated transferee or transferees. The Company hereby initially designates the office of Trustee at
6201 15th Avenue, Brooklyn, New York 11219 as the office
for registration of transfer of this [Global Security] [CVR certificate]. 
 9. As provided in the CVR Agreement and subject to
certain limitations therein set forth, this [Global Security] [CVR Certificate] is exchangeable for one or more CVR certificates or Direct Registration Securities representing the same number of CVRs as represented by this [Global Security] [CVR
Certificate] as requested by the Holder surrendering the same. 
 10. No service charge shall be made for any registration of
transfer or exchange of CVRs, but the Company may require payment of a sum sufficient to cover any documentary, stamp or similar tax or other similar governmental charge payable in connection with any registration of transfer or exchange of
Securities, other than exchanges pursuant to SECTIONS 3.5 or 6.6 of the CVR Agreement not involving any transfer. 
 11. Prior
to the time of due presentment of this [Global Security] [CVR Certificate] for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this [Global Security] [CVR Certificate]
is registered as the owner hereof for all purposes, and neither the Company, the Trustee nor any agent shall be affected by notice to the contrary. 
 12. Neither the Company nor the Trustee has any duty or obligation to the Holder of this [Global Security] [CVR Certificate], except as expressly set forth herein or in the CVR Agreement. 

13. As provided in the CVR Agreement and subject to certain limitations therein set forth, the rights of the Holder of this [Global
Security] [CVR Certificate] shall terminate on the Termination Date. 
 14. Governing Law; Jurisdiction; Venue. THIS
[GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT, OR THE
NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH
THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT OR AS AN INDUCEMENT TO ACCEPT THIS [GLOBAL SECURITY] [CVR CERTIFICATE]) OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED 

 
IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF
THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY STATE COURT IN THE STATE OF DELAWARE OR THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RESPECT OF ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT
OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT (INCLUDING ANY
CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS [GLOBAL SECURITY] [CVR CERTIFICATE] AND THE CVR AGREEMENT OR AS AN INDUCEMENT TO ACCEPT THIS [GLOBAL SECURITY] [CVR
CERTIFICATE]), OR THE SECURITIES, AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID COURTS. 
 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 This is one of the [Global
Securities] [CVR Certificates] referred to in the within-mentioned CVR Agreement. 
  

			
	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC,
	as the Trustee
		
	By:	 	  

		 	Authorized Signatory

 Dated:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]